var title_f7_35_7728="Surface contour leg muscles";
var content_f7_35_7728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surface contours of the lower leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7728=[""].join("\n");
var outline_f7_35_7728=null;
var title_f7_35_7729="Bridge";
var content_f7_35_7729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bridges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie on your back on the floor. Keep the feet on the floor and bend both knees. Place the hands about 12 inches to the side of the body (on the floor). Lift the buttocks 6 to 8 inches off the floor. Hold for 5 seconds, then slowly release. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets. To increase the difficulty, keep the right foot on the floor and lift the left foot off the floor, keeping the left leg straight. Raise the buttocks using the right foot to support the lower body. Switch sides. Repeat 10 to 15 times (one set). Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7729=[""].join("\n");
var outline_f7_35_7729=null;
var title_f7_35_7730="Malignant mesothelioma I MRI";
var content_f7_35_7730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI scan, axial, T1 weighted sequence, shows circumferential pleural thickening. The tumor is of intermediate signal intensity. No invasion of the chest is visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7730=[""].join("\n");
var outline_f7_35_7730=null;
var title_f7_35_7731="Potassium bicarbonate: Drug information";
var content_f7_35_7731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19668?source=see_link\">",
"    see \"Potassium bicarbonate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"    see \"Potassium bicarbonate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13755838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Effervescent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypokalemia:",
"     </b>",
"     Oral: 25 mEq 2-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"      see \"Potassium bicarbonate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypokalemia",
"     </b>",
"     : Oral: Children: 1-4 mEq/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral [effervescent]: Potassium 25 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Effervescent: Potassium 25 mEq [orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium deficiency, hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13892558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperkalemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13892555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13892556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is excreted into breast milk (IOM, 2004). Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13203063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, magnesium (to facilitate potassium repletion), and bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum potassium: 3.5-5.2 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F211673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kaldyum (PL);",
"     </li>",
"     <li>",
"      Kalimat prolongatum (PL);",
"     </li>",
"     <li>",
"      Kalipoz prolongatum (PL);",
"     </li>",
"     <li>",
"      Kalitrans (DE);",
"     </li>",
"     <li>",
"      Kalium (PL);",
"     </li>",
"     <li>",
"      Kalium Chloratum (PL);",
"     </li>",
"     <li>",
"      Kalium Gluconicum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10223 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7731=[""].join("\n");
var outline_f7_35_7731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755838\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211683\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211677\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211682\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211678\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211670\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211660\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211671\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892558\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211663\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299913\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211666\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211667\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892555\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892556\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203063\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203064\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211673\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19668?source=related_link\">",
"      Potassium bicarbonate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=related_link\">",
"      Potassium bicarbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_35_7732="Presacral venous plexus - Fascial relationship";
var content_f7_35_7732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Presacral venous plexus - Fascial relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the location of the presacral venous plexus, presacral facia, and the posterior rectum in the lateral view. The wise surgeon will not violate the presacral fascia so as to avoid the risk of life-threatening hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7732=[""].join("\n");
var outline_f7_35_7732=null;
var title_f7_35_7733="Acne scars";
var content_f7_35_7733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acne scars",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pitted scars due to acne vulgaris are present on the cheek and mandible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7733=[""].join("\n");
var outline_f7_35_7733=null;
var title_f7_35_7734="Hemodynamic tracing acute cardiac tamponade";
var content_f7_35_7734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Intracardiac hemodynamic tracings showing acute cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radial arterial tracing shows tachycardia and extreme pulsus paradoxus. The right atrial and pericardial pressures are equally elevated, but the amount of effusion was very small. Note deeper y descent in the pericardial pressure compared with the right atrial pressure. ECG shows low voltage. Heavy time markings = 1 second.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Pericardium, 2nd ed, Shabetai R (Ed), Kluwer Academic Publishers, Norwell MS 2003. Copyright &copy; 2003 Kluwer Academic Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7734=[""].join("\n");
var outline_f7_35_7734=null;
var title_f7_35_7735="Alprazolam: Pediatric drug information";
var content_f7_35_7735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alprazolam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"    see \"Alprazolam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/29/7637?source=see_link\">",
"    see \"Alprazolam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alprazolam Intensol&trade;;",
"     </li>",
"     <li>",
"      Niravam&trade;;",
"     </li>",
"     <li>",
"      Xanax XR&reg;;",
"     </li>",
"     <li>",
"      Xanax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Alpraz&reg;;",
"     </li>",
"     <li>",
"      Apo-Alpraz&reg; TS;",
"     </li>",
"     <li>",
"      Mylan-Alprazolam;",
"     </li>",
"     <li>",
"      NTP-Alprazolam;",
"     </li>",
"     <li>",
"      Nu-Alpraz;",
"     </li>",
"     <li>",
"      Teva-Alprazolam;",
"     </li>",
"     <li>",
"      Xanax TS&trade;;",
"     </li>",
"     <li>",
"      Xanax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"      see \"Alprazolam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose to effect; use lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;18 years: Immediate release: Dose not established; investigationally in children 7-16 years of age (n=13), initial doses of 0.005 mg/kg or 0.125 mg/dose were given 3 times/day for situational anxiety and increments of 0.125-0.25 mg/dose were used to increase doses to maximum of 0.02 mg/kg/dose or 0.06 mg/kg/day; a range of 0.375-3 mg/day was needed (Pfefferbaum, 1987).",
"     <b>",
"      Note:",
"     </b>",
"     A more recent study in 17 children (8-17 years of age) with overanxious disorder or avoidant disorders used initial daily doses of 0.25 mg for children &lt;40 kg and 0.5 mg for those &gt;40 kg. The dose was titrated at 2-day intervals to a maximum of 0.04 mg/kg/day. Required doses ranged from 0.5-3.5 mg/day with a mean of 1.6 mg/day. Based on clinical global ratings, alprazolam appeared to be better than placebo, however, this difference was",
"     <b>",
"      not",
"     </b>",
"     statistically significant (Simeon, 1992); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anxiety: Immediate release: Initial: 0.25-0.5 mg 3 times/day; titrate dose upward as needed every 3-4 days; maximum dose: 4 mg/day given in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Panic disorder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Initial: 0.5 mg 3 times/day; titrate dose upward as needed every 3-4 days in increments &le;1 mg/day; mean dose used in controlled trials: 5-6 mg/day; maximum dose: 10 mg/day (rarely required)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Initial: 0.5-1 mg once daily; titrate dose upward as needed every 3-4 days in increments &le;1 mg/day; usual dose: 3-6 mg/day; maximum dose: 10 mg/day (rarely required)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Switching from immediate release to extended release: Administer the same total daily dose, but give once daily; if effect is not adequate, titrate dose as above",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alprazolam Intensol&trade;: 1 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xanax&reg;: 0.25 mg, 0.5 mg, 1 mg, 2 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 0.5 mg, 1 mg, 2 mg, 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xanax XR&reg;: 0.5 mg, 1 mg, 2 mg, 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niravam&trade;: 0.25 mg, 0.5 mg, 1 mg, 2 mg [scored; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F132087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: Administer with food to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release tablet: Administer once daily, preferably in the morning; do not crush, chew, or break; swallow whole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally-disintegrating tablet: Do not remove tablets from bottle until right before dose; using dry hands, place tablet on top of tongue. If using one-half of tablet, immediately discard remaining half (half tablet may not remain stable). Administration with water is not necessary (water is not required to aid dissolution or swallowing)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2643702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orally-disintegrating tablet: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture. Discard any cotton packaged inside bottle; reseal bottle tightly.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of generalized anxiety disorder (GAD); symptoms of anxiety (short-term treatment); anxiety associated with depression; management of panic disorder, with or without agoraphobia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ALPRAZolam may be confused with alprostadil, LORazepam, triazolam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Xanax&reg; may be confused with Fanapt&reg;, Lanoxin&reg;, Tenex&reg;, Tylox&reg;, Xopenex&reg;, Zantac&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypotension, palpitation, sinus tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal coordination, agitation, akathisia, ataxia, attention disturbance, cognitive disorder, confusion, depersonalization, depression,derealization, disorientation, disinhibition, dizziness, dream abnormalities, drowsiness, fatigue, fear, hallucination, headache, hypersomnia, hypoesthesia, insomnia, irritability, lethargy, lightheadedness, malaise, memory impairment, mental impairment, nervousness, nightmares, restlessness, sedation, seizure, somnolence, syncope, talkativeness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido decreased/increased, menstrual disorders, sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased/decreased, constipation, diarrhea, dyspepsia, nausea, salivation increased, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, micturition difficulty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, jaundice, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, dysarthria, dyskinesia, dystonia, muscle cramps, muscle twitching, myalgia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, dyspnea, hyperventilation, nasal congestion, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amnesia, angioedema, bilirubin increased, diplopia, falls, homicidal ideation, galactorrhea, gynecomastia, hepatic failure, hepatitis, hyperprolactinemia, hypomania, jaundice, liver enzymes increased, mania, peripheral edema, sleep apnea syndrome, Stevens-Johnson syndrome, suicidal ideation, syncope, tinnitus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alprazolam, any component, or other benzodiazepines; severe uncontrolled pain, narrow-angle glaucoma, severe respiratory depression, pre-existing CNS depression; not to be used in pregnancy or lactation or in patients taking certain medications",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment. Use with caution in patients with renal impairment or predisposition to urate nephropathy; has weak uricosuric properties.  Use with caution in patients with depression, particularly if suicidal risk may be present; episodes of mania or hypomania have occurred in depressed patients treated with alprazolam. Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance and psychological and physical dependence may occur with prolonged use (generally &gt;10 days). Use with caution in patients with respiratory disease. Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated. Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers, and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions. Use with caution in debilitated patients. Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury. Use with caution in obese patients; may have prolonged action when discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal symptoms including seizures have occurred 18 hours to 3 days after abrupt discontinuation; when discontinuing therapy, decrease daily dose by no more than 0.5 mg every 3 days; reduce dose in patients with significant hepatic disease. Concentrated oral solution contains propylene glycol.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F132079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of ALPRAZolam. Management: In patients receiving boceprevir, consider lower alprazolam doses and monitor closely for symptoms of toxicity (including prolonged sedation and respiratory depression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of ALPRAZolam. Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: A high-fat meal eaten &le;2 hours before the dose may increase peak concentrations by &sim;25%. A high-fat meal eaten immediately before the dose may decrease the time to peak concentrations by about 33%. A high-fat meal eaten &ge;1 hour after the dose may increase the time to peak concentrations by about 33%. The extent of absorption (AUC) is not affected by food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally-disintegrating tablet: A high-fat meal may decrease peak concentrations by 25% and delay the time to peak concentrations by 2 hours. The AUC is not affected by food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzodiazepines have the potential to cause harm to the fetus. Alprazolam and its metabolites cross the human placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS status, respiratory rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Rapidly and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: Rate of absorption is increased following night time dosing (versus morning dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.9-1.2 L/kg; distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver, primarily via cytochrome P450 isoenzyme CYP3A; major metabolites: alpha-hydroxy-alprazolam (about half as active as alprazolam), 4-hydroxyalprazolam (active), and a benzophenone metabolite (inactive).",
"     <b>",
"      Note:",
"     </b>",
"     Active metabolites are not likely to contribute to pharmacologic effects due to low levels of activity and low concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Similar for extended and immediate release tablets (&sim;90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 6.3-26.9 hours; mean: 11.2 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Half-life may be 25% longer in Asians compared to Caucasians.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orally-disintegrating tablet: 1.5-2 hours (if given with or without water);",
"     <b>",
"      Note:",
"     </b>",
"     Time to peak serum concentration occurs &sim;15 minutes earlier when taken with water (versus without)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excretion of metabolites and parent compound in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/29/7637?source=see_link\">",
"      see \"Alprazolam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use; avoid alcohol; limit caffeine; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If used for an extended period of time, long-term usefulness of alprazolam should be periodically re-evaluated for an individual patient.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (Alprazolam Intensol&trade;: 1 mg/mL [dye free, ethanol free, sugar free; contains propylene glycol])",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL oral suspension may be made with tablets and one of three different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;, or a 1:4 mixture of cherry syrup with Simple Syrup, NF). Crush sixty 2 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add a quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable for 60 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein GA, Garfinkel BD, and Borchardt CM, &ldquo;Comparative Studies of Pharmacotherapy for School Refusal,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1990, 29(5):773-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7735/abstract-text/2228932/pubmed\" id=\"2228932\" target=\"_blank\">",
"        2228932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeVane CL, Hill M, and Antal EJ, &ldquo;Therapeutic Drug Monitoring of Alprazolam in Adolescents With Asthma,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1998, 20(3):257-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7735/abstract-text/9631921/pubmed\" id=\"9631921\" target=\"_blank\">",
"        9631921",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfefferbaum B, Overall JE, Boren HA, et al, &ldquo;Alprazolam in the Treatment of Anticipatory and Acute Situational Anxiety in Children With Cancer,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1987, 26(4):532-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7735/abstract-text/3654506/pubmed\" id=\"3654506\" target=\"_blank\">",
"        3654506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG and Ferguson HB, &ldquo;Alprazolam Effects in Children With Anxiety Disorders,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1987, 32(7):570-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7735/abstract-text/ 3315169 /pubmed\" id=\" 3315169 \" target=\"_blank\">",
"        3315169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG, Ferguson HB, Knott V, et al, &ldquo;Clinical, Cognitive, and Neurophysiological Effects of Alprazolam in Children and Adolescents With Overanxious and Avoidant Disorders,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1992, 31(1):29-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7735/abstract-text/1537778/pubmed\" id=\"1537778\" target=\"_blank\">",
"        1537778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13346 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7735=[""].join("\n");
var outline_f7_35_7735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132040\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132041\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050881\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050874\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132014\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131999\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132087\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050886\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2643702\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132095\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132093\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050889\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050873\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050872\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132079\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132008\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050892\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132009\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132025\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050880\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050871\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050888\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050878\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050890\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806214\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=related_link\">",
"      Alprazolam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/29/7637?source=related_link\">",
"      Alprazolam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_35_7736="Assays of the renin-angiotensin-aldosterone system in adrenal disease";
var content_f7_35_7736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Michael Stowasser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7736/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/35/7736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the renin-angiotensin-aldosterone system has recently assumed a much greater role in clinical practice, particularly in the evaluation of patients with hypertension. This is mainly attributable to the growing appreciation that primary aldosteronism is a much more common cause of hypertension than previously thought, accounting for as many as 5 to 10 percent of cases, and that most patients lack hypokalemia as a clinical clue. As a result, guidelines advocate screening for primary aldosteronism by measurement of the plasma",
"    <span class=\"nowrap\">",
"     aldosterone/renin",
"    </span>",
"    ratio rather than that of plasma potassium (which is much less sensitive) and among a much wider population of hypertensives than previously [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the renin-angiotensin-aldosterone system is often evaluated in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia or hyperkalemia who may have hyperaldosteronism (or other forms of real or apparent mineralocorticoid excess) or hypoaldosteronism, respectively.",
"     </li>",
"     <li>",
"      Adrenal insufficiency (to distinguish primary from secondary).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of renin, angiotensin, and aldosterone measurements will be reviewed here. The approach to the patient with potential mineralocorticoid excess or hypoaldosteronism is discussed separately. In addition, the physiology of the renin-angiotensin system and the control of aldosterone are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin can be measured in terms of its enzymatic activity (plasma renin activity [PRA]), or its mass (active renin concentration). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Plasma renin activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasma renin activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma renin activity is measured by incubating plasma at 37 degrees Celsius without addition of angiotensinogen (renin substrate), relying instead on endogenous angiotensinogen in the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/2\">",
"     2",
"    </a>",
"    ]. Renin cleaves angiotensinogen to produce a decapeptide, angiotensin I, which can be measured by radioimmunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma renin activity is expressed as the amount of angiotensin I generated per unit of time. The recommended incubation time, 90 minutes, should be extended up to 18 hours for samples with levels less than 1",
"    <span class=\"nowrap\">",
"     ng/mL/h,",
"    </span>",
"    in order to permit enough generation of angiotensin I to ensure assay reproducibility at the lower end of the scale [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/4\">",
"     4",
"    </a>",
"    ]. Subtracting the amount of preformed angiotensin I in a control aliquot incubated at 4&deg; Celsius is suggested, but this may reduce the reproducibility of the test [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasma renin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentration of the active (cleaved) form of renin can be measured by radioimmunoassay, but is usually measured by automated immunometric assay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/5\">",
"     5",
"    </a>",
"    ]. Since renin does not affect blood pressure directly, but only through angiotensin, plasma renin activity is a better reflection of angiotensin II concentrations. Active renin concentration can be influenced by substrate concentrations. As an example, with estrogen administration, substrate increases, and renin concentration falls to maintain angiotensin II concentrations in the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Automated immunometric assays for measuring active renin have been adopted in many laboratories, because they are faster and more convenient than plasma renin activity or renin concentration radioimmunoassays. However, these methods are not yet sufficiently accurate to supplant plasma renin activity as a diagnostic test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal, morning plasma renin activity for seated subjects ranges from about 1 to 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    per h (0.8 to 3.0",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    per h). Corresponding active renin concentrations are 8 to 35",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Factors that affect renin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors",
"    that affect renin levels include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium intake &mdash; Renin may be stimulated by dietary salt restriction and suppressed by consumption of a high salt diet.",
"     </li>",
"     <li>",
"      Age &mdash; Renin levels gradually fall as renal function declines.",
"     </li>",
"     <li>",
"      Time of day &mdash; Renin levels show a diurnal rhythm, being highest in the early morning upon awakening and falling during the day [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posture &mdash; Following assumption of upright posture, the translocation of blood into the lower limbs is associated with an increase in renin, released from juxtaglomerular cells in response to a fall in renal perfusion pressure and an increase in sympathetic output and beta adrenergic receptor stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medication use &mdash; Renin is increased with diuretics (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      ), dihydropyridine calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Levels are decreased by beta-blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , or alpha-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      (all of which reduce beta-sympathetic stimulation of renin release), or non-steroidal anti-inflammatory agents (which promote salt retention and also inhibit renal prostaglandin production). In order to facilitate interpretation of aldosterone and renin levels, these agents should, when possible, be ceased for at least two and preferably four weeks (longer, eg, &gt;6 weeks, in the case of diuretics) before sample collection. During this period, antihypertensive medications that have minimal effects on renin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      slow release, to which can be added",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alpha-blockers such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      ) can be used in place of the above interfering agents in order to maintain control of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/1,7\">",
"       1,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Luteal phase and pregnancy &mdash; Renin levels are higher in the luteal phase of the menstrual cycle and during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/10,11\">",
"       10,11",
"      </a>",
"      ], in part because of the mineralocorticoid antagonist activity of progesterone (high concentrations of progesterone antagonize aldosterone action at the mineralocorticoid receptor).",
"     </li>",
"     <li>",
"      Chronic kidney disease &mdash; In chronic kidney disease, renal renin-producing capacity is reduced, and salt-retention contributes to renin suppression.",
"     </li>",
"     <li>",
"      Race &mdash; Renin levels are lower in black than white subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interpretation in adrenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal diseases have a variable effect on renin levels, being determined primarily by whether the disease results in an increase or a decrease in the secretion of mineralocorticoids (which induce volume expansion, resulting in suppression of renin release).",
"   </p>",
"   <p>",
"    Renin concentrations are usually",
"    <strong>",
"     low",
"    </strong>",
"    in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary aldosteronism, in which aldosterone production is excessive (relative to body sodium status), and independent of its normal regulator,",
"      <span class=\"nowrap\">",
"       renin/angiotensin",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Primary aldosteronism may be due to an aldosterone-producing adrenocortical tumor (adenoma or, rarely, carcinoma), bilateral adrenal hyperplasia, or glucocorticoid-remediable aldosteronism (familial hyperaldosteronism type I). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with 11-beta-hydroxylase or 17-alpha-hydroxylase deficiency (due to mutations in CYP11B1 and CYP17 respectively), which are hypertensive forms of congenital adrenal hyperplasia associated with excessive production of the mineralocorticoid deoxycorticosterone (DOC), driven by adrenocorticotropin (ACTH, levels of which are high as a result of deficient cortisol production). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=see_link\">",
"       \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary glucocorticoid resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/14\">",
"       14",
"      </a>",
"      ], which is again associated with ACTH simulation and excessive DOC production causing hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with DOC-producing adrenal tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"       \"Approach to the patient with hypertension and hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ectopic ACTH syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/16\">",
"       16",
"      </a>",
"      ], in which cortisol levels may be high enough to overwhelm the 11-beta-hydroxysteroid dehydrogenase type 2 enzyme (which normally, by converting cortisol to cortisone, prevents excessive stimulation of the mineralocorticoid receptor) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, the high levels of ACTH may lead to excessive production of DOC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link&amp;anchor=H9#H9\">",
"       \"Causes and pathophysiology of Cushing's syndrome\", section on 'Ectopic ACTH syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    They are usually",
"    <strong>",
"     normal",
"    </strong>",
"    in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary adrenal insufficiency (ie, hypopituitarism or isolated ACTH deficiency). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cushing's syndrome, but they can be low when there is a marked degree of hypercortisolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    They are usually",
"    <strong>",
"     high",
"    </strong>",
"    in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary adrenal insufficiency, including Addison's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"       \"Clinical manifestations of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with congenital adrenal hyperplasia due to deficiencies in either steroid acute regulatory protein (due to mutations in StAR), side-chain cleavage enzyme (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (HSD3B2), 21-hydroxylase (CYP21A2) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/17\">",
"       17",
"      </a>",
"      ] or aldosterone synthase (CYP11B2) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/18\">",
"       18",
"      </a>",
"      ] in which deficient production of steroids with mineralocorticoid activity leads to salt-wasting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interpretation in non-adrenal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin levels are",
"    <strong>",
"     low",
"    </strong>",
"    in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liddle's syndrome, in which gain-of-function mutations in the epithelial sodium channel lead to sodium retention, hypertension, and usually hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital or acquired (eg, through ingestion of licorice) deficiency of 11-beta-hydroxysteroid dehydrogenase type 2, resulting in activation of the mineralocorticoid receptor by cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"       \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations of the mineralocorticoid receptor gene, which cause a modest constitutive activation of the receptor, and permit progesterone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      to act as agonists rather than antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hereditary hypertension with hyperkalemia and normal GFR (pseudohypoaldosteronism type 2 or Gordon's syndrome), which is associated with sodium and potassium retention due to defects in genes encoding serine-threonine kinases (WNK1 and WNK4) expressed in the distal nephron [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H13#H13\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike primary aldosteronism, aldosterone concentrations are chronically suppressed (as a result of chronic suppression of renin secretion) in all of these salt-dependent, low-renin forms of hypertension, with the exception of pseudohypoaldosteronism type 2, in which chronically elevated plasma potassium concentrations limit suppression of aldosterone.",
"   </p>",
"   <p>",
"    Renin levels are also often low in patients with chronic renal impairment, in which reduced renin-producing capacity and salt-retention contribute to renin suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renin levels are",
"    <strong>",
"     high",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with \"renovascular\" forms of hypertension and reninoma (levels may also be normal).",
"     </li>",
"     <li>",
"      In malignant hypertension.",
"     </li>",
"     <li>",
"      In pseudohypoaldosteronism type 1, in which salt wasting occurs due to resistance to the actions of aldosterone, resulting from mutations in the gene encoding the epithelial sodium channel (autosomal recessive) or mineralocorticoid receptor (autosomal dominant or sporadic). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H8#H8\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Pseudohypoaldosteronism type 1'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In Bartter and Gitelman syndromes, in which mutations in renal tubular ion channels also lead to salt wasting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In heart failure, hepatic cirrhosis and nephrotic syndrome, in which edema is associated with relative intravascular hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALDOSTERONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum aldosterone is measured by radioimmunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/26\">",
"     26",
"    </a>",
"    ]. The assay requires a high-affinity, highly specific antibody because aldosterone concentrations in serum are less than 1 percent those of cortisol. Faster, more convenient methods of directly measuring aldosterone are available, using immunometric techniques and automated machinery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like the automated active renin concentration assay, considerable work is required to validate and improve these methods before they can be considered accurate enough to use for diagnostic purposes (eg, evaluating patients for possible primary aldosteronism).",
"   </p>",
"   <p>",
"    Concerns with the",
"    <strong>",
"     automated",
"    </strong>",
"    aldosterone assay include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential for false negative suppression tests. In an analysis, aldosterone levels were below the assay's limit of detection for over half the samples collected from normal subjects and nearly half those from patients with essential hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-specific interference, possibly due to the brevity of the \"wash\" immediately prior to chemiluminescence, leading to an unacceptably high \"blank\" value in bilaterally adrenalectomised and Addisonian patients.",
"     </li>",
"     <li>",
"      Weaknesses of the assay system: it is calibrated by only a two-point re-calibration against a stored master curve, and that the two calibrators are reconstituted lyophilized aldosterone. Inclusion of blanks using plasma from bilaterally adrenalectomised or Addisonian patients, as well as calibration, using plasma pools from persons with known low, medium or high values, would permit very valuable, in-house, ongoing evaluation of the system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Highly accurate and reproducible methods of measuring aldosterone using high performance liquid chromatography and tandem mass spectrometry have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/29\">",
"     29",
"    </a>",
"    ]. The incorporation of new semi-automated technology has meant that these methods can generate results rapidly and with relatively high throughput, and will therefore be applicable to the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morning serum (and plasma) aldosterone concentrations range from 5 to 30",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (140 to 830",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    in seated normal subjects with unrestricted salt intakes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/30\">",
"     30",
"    </a>",
"    ]. Concentrations are lower in black than in white subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/31\">",
"     31",
"    </a>",
"    ]. Other aspects that affect aldosterone concentrations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diurnal variation &mdash; There is a diurnal variation in serum aldosterone concentrations, with highest concentrations at about the time of awakening and lowest in the evening [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum aldosterone concentrations are normally related to extracellular fluid volume, being increased by dietary sodium restriction or sodium diuresis, and decreased by oral or intravenous sodium loading.",
"     </li>",
"     <li>",
"      Aldosterone concentrations tend to be increased modestly in the luteal phase of the menstrual cycle and are increased up to 10 times normal by the third trimester of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following assumption of upright posture, the translocation of blood into the lower limbs is associated with a rise in plasma aldosterone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/33\">",
"       33",
"      </a>",
"      ]. This results partly from an increase in renin [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/9\">",
"       9",
"      </a>",
"      ]. In addition, reduced metabolic clearance of aldosterone occurs due to reduced hepatic blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In practice, for most situations where aldosterone and renin levels are to be assessed, most centers draw a morning ambulatory upright sample. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Protocol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interpretation in adrenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum aldosterone levels are usually",
"    <strong>",
"     low",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with 11-beta-hydroxylase or 17-alpha-hydroxylase deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/34,35\">",
"       34,35",
"      </a>",
"      ], which are associated with excessive production of DOC (and possibly corticosterone in the latter condition).",
"     </li>",
"     <li>",
"      In some patients with Cushing's syndrome, with the extent of suppression depending upon the degree of hypersecretion of cortisol and other salt-retaining steroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum aldosterone levels are usually",
"    <strong>",
"     low",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     or undetectable:",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In primary adrenal insufficiency, and may be normal or low in patients with chronic corticotroph deficiency.",
"     </li>",
"     <li>",
"      In patients with deficiencies of either steroid acute regulatory protein, side-chain cleavage enzyme, 3-beta-hydroxysteroid dehydrogenase, and aldosterone synthase, since aldosterone synthesis is directly impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Levels are",
"    <strong>",
"     high",
"    </strong>",
"    in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with primary aldosteronism, but are often normal (inappropriately, in the face of renin suppression) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/7,9\">",
"       7,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interpretation in other (non-adrenal) conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone levels may be",
"    <strong>",
"     low",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with Liddle's syndrome, 11-beta-hydroxysteroid dehydrogenase deficiency, primary glucocorticoid resistance, 11-beta-hydroxylase and 17-alpha-hydroxylase deficiencies, ectopic ACTH syndrome, or activating mutations of the mineralocorticoid receptor (see above).",
"     </li>",
"     <li>",
"      In hyporeninemic hypoaldosteronism associated with diabetic nephropathy and some other renal disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Or normal in pseudohypoaldosteronism type 2 (see above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Levels may be",
"    <strong>",
"     high",
"    </strong>",
"    in patients with secondary hyperaldosteronism in which raised aldosterone is secondary to raised",
"    <span class=\"nowrap\">",
"     renin/angiotensin",
"    </span>",
"    levels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In renal artery stenosis or reninoma (causing renin-dependent hypertension).",
"     </li>",
"     <li>",
"      In malignant hypertension.",
"     </li>",
"     <li>",
"      In pseudohypoaldosteronism type 1 (resulting in resistance to aldosterone action). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H8#H8\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Pseudohypoaldosteronism type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In heart failure, cirrhosis and nephrotic syndrome, in which edema is associated with relative intravascular hypovolemia and (in the case of heart failure and hepatic cirrhosis) aldosterone metabolism may be impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Or normal in Bartter syndrome and Gitelman syndrome, in which hypokalemia limits the aldosterone rise that results from stimulation by raised renin levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urine aldosterone excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone, in the form of its 18-glucuronide, is measured by radioimmunoassay. Its excretion varies from about 5 to 19 mcg (14 to 53 nmol) per 24 hours. The excretion of tetrahydroaldosterone-18-glucuronide, a more abundant metabolite, ranges from about 12 to 65 mcg (33 to 178 nmol) per 24 hours.",
"   </p>",
"   <p>",
"    As with",
"    <span class=\"nowrap\">",
"     aldosterone/renin",
"    </span>",
"    ratio testing, diuretics (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) should be withheld for at least six weeks before testing, and beta-blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , dihydropyridine calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and NSAIDs for at least two weeks (and preferably four) before urinary aldosterone excretion is measured. Hypokalemia should be corrected with KCl supplements and the patient should be instructed to follow a diet with a liberal sodium intake.",
"   </p>",
"   <p>",
"    Urinary aldosterone excretion varies in patients with adrenal disease in a manner similar to that described above for serum aldosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Aldosterone secretory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone secretion or production rates can be measured by isotopic dilution methods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/13,34\">",
"     13,34",
"    </a>",
"    ]. Aldosterone, labeled with a radioactive or nonradioactive isotope, is injected intravenously. Either a series of blood samples or a 24-hour urine collection is then obtained. The extent of dilution of labeled aldosterone by endogenous unlabeled aldosterone (ie, the decrease in specific activity) is determined and can be used to calculate the amount of endogenous aldosterone secreted during the interval.",
"   </p>",
"   <p>",
"    Because these assays are technically demanding, time-consuming, and expensive, and the information required for clinical decisions can usually be obtained by other means, steroid secretion rates are rarely measured nowadays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the renin-angiotensin-aldosterone system has recently assumed a much greater role in clinical practice, particularly in the evaluation of patients with hypertension. This is mainly attributable to the growing appreciation that primary aldosteronism is a much more common cause of hypertension than previously thought, accounting for as many as 5 to 10 percent of cases, and that most patients lack hypokalemia as a clinical clue.",
"   </p>",
"   <p>",
"    In addition, the renin-angiotensin-aldosterone system is often evaluated in patients with hypokalemia or hyperkalemia who may have hyperaldosteronism (or other forms of real or apparent mineralocorticoid excess) or hypoaldosteronism, respectively, and adrenal insufficiency (to distinguish primary from secondary).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin can be measured in terms of its enzymatic activity (plasma renin activity [PRA]), or its mass (active renin concentration). Serum aldosterone is measured by radioimmunoassay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal, morning plasma renin activity for seated subjects ranges from about 1 to 4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      per h (0.8 to 3.0",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      per h). Levels may be affected by sodium intake, age, time of day, upright posture, medication use, and endogenous progesterone. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Factors that affect renin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morning serum (and plasma) aldosterone concentrations range from 5 to 30",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (140 to 830",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      in seated normal subjects with unrestricted salt intakes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/30\">",
"       30",
"      </a>",
"      ]. Concentrations are lower in black than in white subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7736/abstract/31\">",
"       31",
"      </a>",
"      ]. Like plasma renin activity, aldosterone levels are affected by sodium intake, time of day, upright posture, and endogenous progesterone. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Normal values'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/1\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/2\">",
"      Haber E, Koerner T, Page LB, et al. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969; 29:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/3\">",
"      Workman RJ, Sussman CR, Burkitt DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med 1979; 93:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/4\">",
"      Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med 1975; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/5\">",
"      Ferrari P, Shaw SG, Nicod J, et al. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/6\">",
"      Laragh JH, Sealey J, Brunner HR. The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. Am J Med 1972; 53:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/7\">",
"      Stowasser, M, Gordon, RD. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist 2004; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/8\">",
"      Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966; 45:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/9\">",
"      Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/10\">",
"      Michelakis AM, Yoshida H, Dormois JC. Plasma renin activity and plasma aldosterone during the normal menstrual cycle. Am J Obstet Gynecol 1975; 123:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/11\">",
"      Weinberger MH, Kramer NJ, Grim CE, Petersen LP. The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women. J Clin Endocrinol Metab 1977; 44:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/12\">",
"      Sever PS, Peart WS, Meade TW, et al. Ethnic differences in blood pressure with observations on noradrenaline and renin. 1. A working population. Clin Exp Hypertens 1979; 1:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/13\">",
"      CONN JW. PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM. IMPORTANCE IN DIFFERENTIAL DIAGNOSIS AND IN RESEARCH OF ESSENTIAL HYPERTENSION. JAMA 1964; 190:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/14\">",
"      Arai K, Chrousos GP. Syndromes of glucocorticoid and mineralocorticoid resistance. Steroids 1995; 60:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/15\">",
"      Irony I, Biglieri EG, Perloff D, Rubinoff H. Pathophysiology of deoxycorticosterone-secreting adrenal tumors. J Clin Endocrinol Metab 1987; 65:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/16\">",
"      Walker BR, Campbell JC, Fraser R, et al. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992; 37:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/17\">",
"      Simpoulos AP, Marshall JR, Delea CS, Bartter FC. Studies on the deficiency of 21-hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1971; 32:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/18\">",
"      Shizuta Y, Kawamoto T, Mitsuuchi Y, et al. Inborn errors of aldosterone biosynthesis in humans. Steroids 1995; 60:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/19\">",
"      Warnock DG. Liddle syndrome: genetics and mechanisms of Na+ channel defects. Am J Med Sci 2001; 322:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/20\">",
"      Stewart PM. 11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Clin Endocrinol (Oxf) 1996; 44:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/21\">",
"      White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am 1994; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/22\">",
"      Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/23\">",
"      Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/24\">",
"      Wilson FH, Disse-Nicod&egrave;me S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/25\">",
"      McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/26\">",
"      Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab 1970; 30:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/27\">",
"      Perschel FH, Schemer R, Seiler L, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/28\">",
"      Schirpenbach C, Seiler L, Maser-Gluth C, et al. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/29\">",
"      Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009; 55:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/30\">",
"      Al-Dujaili EA, Edwards CR. The development and application of a direct radioimmunoassay for plasma aldosterone using 125I-labeled ligand--comparison of three methods. J Clin Endocrinol Metab 1978; 46:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/31\">",
"      Pratt JH, Jones JJ, Miller JZ, et al. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med 1989; 321:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/32\">",
"      Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/33\">",
"      Tuck ML, Dluhy RG, Williams GH. Sequential responses of the renin-angiotensin-aldosterone axis to acute postural change: effect of dietary sodium. J Lab Clin Med 1975; 86:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/34\">",
"      Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7736/abstract/35\">",
"      D'Armiento M, Reda G, Kater C, et al. 17 alpha-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family. J Clin Endocrinol Metab 1983; 56:697.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 167 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7736=[""].join("\n");
var outline_f7_35_7736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasma renin activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasma renin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Factors that affect renin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interpretation in adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interpretation in non-adrenal conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALDOSTERONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interpretation in adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interpretation in other (non-adrenal) conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine aldosterone excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aldosterone secretory rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_35_7737="Aripiprazole: Pediatric drug information";
var content_f7_35_7737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aripiprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"    see \"Aripiprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17350?source=see_link\">",
"    see \"Aripiprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abilify Discmelt&reg;;",
"     </li>",
"     <li>",
"      Abilify Maintena&trade;;",
"     </li>",
"     <li>",
"      Abilify&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9490633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abilify&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"      see \"Aripiprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution may be substituted for the oral tablet on a mg-per-mg basis, up to 25 mg. Patients receiving 30 mg tablets should be given 25 mg oral solution. Orally disintegrating tablets (Abilify Discmelt&reg;) are bioequivalent to the immediate release tablets (Abilify&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Attention-Deficit/Hyperactivity Disorder (ADHD):",
"     </b>",
"     Limited data available: Children &ge;8 years and Adolescents: Oral: Initial: 2.5 mg/day; may increase on a weekly basis by 2.5 mg/day increments as tolerated; maximum  daily dose: 10 mg/day; dosing based on an open-label, pilot study (n=23, age: 8-12 years) which reported significant improvement in ADHD outcome scores without an impact on cognitive measures (positive or negative); mean final dose: 6.7 &plusmn; 2.4 mg/day (Findling, 2008). Other aripiprazole published reports in pediatric and adolescent patients in which ADHD is a comorbid diagnosis within the study population exist; however, effectiveness in ADHD was not a reported primary outcome measure (Bastiaens, 2009; Budman, 2008; Findling, 2009; Murphy, 2009; Valicenti-McDermott, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Autism; treatment of associated irritiability (including aggression, deliberate self-injurious behavior, temper tantrums, and quickly changing moods):",
"     </b>",
"     Children and Adolescents 6-17 years: Oral: Initial: 2 mg daily for 7 days, followed by 5 mg daily; subsequent dose increases may be made in 5 mg increments every &ge;7 days, up to a maximum daily dose of 15 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bipolar I disorder (acute manic or mixed episodes):",
"     </b>",
"     Children and Adolescents 10-17 years: Oral: Initial: 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments, up to a maximum daily dose of 30 mg/",
"     <b>",
"      day",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     The safety of doses &gt;30 mg/day has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Conduct disorder (CD); aggression:",
"     </b>",
"     Limited data available: Children &ge;6 years and Adolescents: Oral: Initial: Patient weight &lt;25 kg: 1 mg/day; 25-50 kg: 2 mg/day; 51-70 kg: 5 mg/day; &gt;70 kg: 10 mg/day; may titrate after 2 weeks to clinical effectiveness; maximum daily dose: 15 mg/",
"     <b>",
"      day",
"     </b>",
"     . Dosing based on an open-label, prospective study (n=23; age: 6-17 years) which evaluated pharmacokinetics and effectiveness in patients with a primary diagnosis of CD (with or without comorbid ADHD); results showed improvement in CD symptom scores with only minor improvements in cognition (Findling, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) or Asperger's Disorder; treatment of associated irritability (aggression, self-injury, tantrums):",
"     </b>",
"     Limited data available: Children &ge;4 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preschool age: Initial dose: 1.25 mg/day with titration every &ge;5 days in 1.25 mg/day increments as tolerated or clinically indicated (Masi, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prepubertal children: Initial dose: 1.25-2.5 mg/day with titration every 3-5 days in 1.25-2.5 mg/day increments as tolerated or clinically indicated; maximum daily dose: 15 mg/",
"     <b>",
"      day",
"     </b>",
"     (Masi, 2009; Stigler, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Initial dose: 2.5-5 mg/day with titration every 5 days in 2.5-5 mg/day increments as tolerated or clinically indicated; doses &gt;5 mg/day were divided twice daily; if sleep disorder was reported, the dose was given in morning and/or at lunchtime (Masi, 2009); maximum daily dose: 15 mg/",
"     <b>",
"      day",
"     </b>",
"     (Stigler, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     An open-labeled, pilot study (n=25; mean age: 8.6 years; range: 5-17 years) reported an 88% response with a mean final dose of 7.8 mg/day (range: 2.5-15 mg/day) (Stigler, 2009). A retrospective, noncontrolled, open-label study of 34 PDD patients (mean age: 10.2 years; range: 4-15 years) included 10 patients with autistic disorder and 24 patients with PDD-NOS reported a mean final dose: 8.1 &plusmn; 4.9 mg/day and an overall response rate of 32.4% (29.2% in patients with PDD-NOS) (Masi, 2009). In a retrospective chart review of children and adolescents with developmental disability and a wide range of psychiatric disorders (n=32; age: 5-19 years), a mean starting dose of aripiprazole of 7.1 &plusmn; 0.32 mg/day and a mean maintenance dose of 10.55 &plusmn; 6.9 mg/day was used; a response rate of 56% was reported for the overall population. However, a study population subset analysis in patients with mental retardation (n=18) showed a lower response rate in patients with mental retardation with PDD-NOS (38%) than in patients with mental retardation without PDD-NOS (100%) (Valicenti-McDermott, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Adolescents 13-17 years: Oral: Initial: 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments up to a maximum daily dose of 30 mg/",
"     <b>",
"      day",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     30 mg/day was",
"     <b>",
"      not",
"     </b>",
"     found to be more effective than the 10 mg/day dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tourette's syndrome, tic disorders:",
"     </b>",
"     Limited data available: Children &ge;7 years and Adolescents: Oral: Initial: 1.25-5 mg/day; daily doses were increased by 1.25-2.5 mg weekly or by 5 mg every 2 weeks; maximum daily dose: 20 mg/day. Dosing based on several open-label trials and a retrospective case series; reported mean required doses ranged from 3.3-11.7 mg/day (Budman, 2008; Murphy, 2009; Seo, 2008; Yoo, 2007; Yoo, 2011).  Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute agitation (schizophrenia/bipolar mania):",
"     </b>",
"     I.M.: 9.75 mg as a single dose (range: 5.25-15 mg); may repeat at &ge;2-hour intervals to a maximum daily dose of 30 mg/",
"     <b>",
"      day",
"     </b>",
"     );",
"     <b>",
"      Note:",
"     </b>",
"     A dose of 15 mg was",
"     <b>",
"      not",
"     </b>",
"     shown to be more effective than 9.75 mg dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder (acute manic or mixed episodes):",
"     </b>",
"     Oral: Initial: 15 mg once daily (as monotherapy or as adjunctive therapy with lithium or valproate); usual: 15 mg once daily; may be increased to a maximum daily dose of 30 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;30 mg/day have not been evaluated. Continue for up to 6 weeks; efficacy of continued treatment &gt; 6 weeks has not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression (adjunctive with antidepressants):",
"     </b>",
"     Oral: Initial: 2-5 mg/day; dosage adjustments of up to 5 mg/day may be made in intervals of &ge;1 week;  usual dose: 2-15 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Oral: Initial: 10-15 mg once daily; usual: 10-15 mg once daily; may be increased to a maximum daily dose of 30 mg/",
"     <b>",
"      day",
"     </b>",
"     . Dosage titration should not be more frequent than every 2 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Doses higher than 10-15 mg once daily were",
"     <b>",
"      not",
"     </b>",
"     found to be more effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concurrent CYP450 inducer or inhibitor therapy:",
"     </b>",
"     Children, Adolescents, and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CYP3A4 inducers (eg, carbamazepine): Aripiprazole dose should be doubled; dose should be subsequently reduced if concurrent inducer agent discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strong CYP3A4 inhibitors (eg, ketoconazole): Aripiprazole dose should be reduced to  50% of the usual dose, and proportionally increased upon discontinuation of the inhibitor agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CYP2D6 inhibitors (eg, fluoxetine, paroxetine): Aripiprazole dose should be reduced to 50% of the usual dose, and proportionally increased upon discontinuation of the inhibitor agent.",
"     <b>",
"      Note:",
"     </b>",
"     When aripiprazole is administered as adjunctive therapy to patients with MDD, the dose should",
"     <b>",
"      not",
"     </b>",
"     be adjusted, follow usual dosing recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CYP3A4 and CYP2D6 inhibitors: Aripiprazole dose should be reduced to 25% of the usual dose. In patients receiving inhibitors of differing (eg, moderate 3A4/strong 2D6) or same (eg, moderate 3A4/moderate 2D6) potencies (excluding concurrent strong inhibitors), further dosage adjustments can be made to achieve the desired clinical response. In patients receiving strong CYP3A4 and 2D6 inhibitors, aripiprazole dose is proportionally increased upon discontinuation of one or both inhibitor agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment based on CYP2D6 metabolizer status:",
"     </b>",
"     Children, Adolescents, and Adults: Oral: Aripiprazole dose should be reduced to 50% of the usual dose in CYP2D6 poor metabolizers and to 25% of the usual dose in poor metabolizers receiving a concurrent strong CYP3A4 inhibitor; subsequently adjust dose for favorable clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for suspension, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify Maintena&trade;: 300 mg, 400 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify&reg;: 7.5 mg/mL (1.3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify&reg;: 1 mg/mL (150 mL) [contains fructose 200 mg/mL, propylene glycol, sucrose 400 mg/mL; orange cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify&reg;: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify Discmelt&reg;: 10 mg [contains phenylalanine 1.12 mg/tablet; creme de vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abilify Discmelt&reg;: 15 mg [contains phenylalanine 1.68 mg/tablet; creme de vanilla flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16321186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Abilify Maintena: FDA approved March 2013; availability anticipated in March 2013.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Abilify&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085804.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085804.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Abilify Maintena&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342207.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342207.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F999047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (all dosage forms): May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally-disintegrating tablet: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue. Tablet dissolves rapidly in saliva and may be swallowed without liquid; if needed, tablet can be taken with liquid. Do not split tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: For I.M. use only; do not administer SubQ or I.V.; inject slowly into deep muscle mass",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F999025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect injection from light; store in original container; keep in carton until ready to use. Use oral solution within 6 months after opening, but not beyond the manufacturer expiration date.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Acute and maintenance treatment of schizophrenia (FDA approved in ages &ge;13 years and adults); acute and maintenance treatment of bipolar disorder (with acute manic or mixed episodes) (FDA approved in ages &ge;10 years and adults); adjunctive therapy (to lithium or valproate) for acute treatment of bipolar disorder (with acute manic or mixed episodes) (FDA approved in ages &ge;10 years and adults); treatment of irritability associated with autistic disorder (including symptoms of aggression, deliberate self-injurious behavior, temper tantrums, quickly changing moods) (FDA approved in ages 6-17 years); adjunctive treatment (to antidepressants) of major depressive disorder (FDA approved in adults). Has also been used in children and adolescents for treatment of ADHD, conduct disorders, Tourette's syndrome, and irritability associated with other pervasive developmental disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Acute treatment of agitation associated with schizophrenia or bipolar disorder (manic or mixed) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F136828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Abilify&reg; may be confused with Ambien&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       ARIPiprazole may be confused with proton pump inhibitors (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, RABEprazole)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       There are two formulations available for intramuscular administration: Abilify&reg; is an immediate release short-acting formulation and Abilify Maintena&trade; is an extended-release formulation. These products are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema (peripheral), hypertension, orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, akathisia, anxiety, coordination impaired, dizziness, dystonia, EPS (dose related), fatigue (dose related), headache, hypersomnia, insomnia, irritability, lethargy, lightheadedness, pain, pyrexia, restlessness, sedation (dose related), suicidal ideation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, appetite decreased/increased, constipation, diarrhea, dyspepsia, nausea, salivation increased (dose related), toothache, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, CPK increased, dyskinesia, extremity pain, myalgia, spasm, stiffness, tremor (dose related), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Aspiration pneumonia, cough, dyspnea, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggression, agranulocytosis, alopecia, akinesia, amenorrhea, anaphylactic reaction, anger, angina pectoris, angioedema, anorexia, anorgasmia, atrial fibrillation, atrial flutter, atrioventricular block, bilirubin increased, bradycardia, bradykinesia, breast pain, cardiopulmonary failure, cardiorespiratory arrest, catatonia, cerebrovascular accident, choreoathetosis, cogwheel rigidity, creatinine increased, delirium, diplopia, diabetes mellitus, DKA, dysphagia, edema (facial), erectile dysfunction, esophagitis, extrasystoles, GGT increased, glycosylated hemoglobin increased, gynecomastia, heat stroke, hepatic enzyme increased, hepatitis, homicidal ideation, hostility, hyper-/hypoglycemia, hyper-/hypotonia, hyperlipidemia, hypersensitivity, hypokalemia, hypokinesia, hyponatremia, hypotension, hypothermia, intentional self injury, jaundice, lactate dehydrogenase increased, leukopenia, libido changes, memory impairment, menstrual irregularities, MI, muscle rigidity, myocardial ischemia, myoclonus, neutropenia, nocturia, oropharyngeal spasm, palpitation, pancreatitis, parkinsonism, photophobia, polydypsia, polyuria, priapism, prolactin increased, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolonged, rhabdomyolysis, seizure (grand mal), speech disorder, suicide, suicide attempt, supraventricular tachycardia, swollen tongue, syncope, tardive dyskinesia, thrombocytopenia, tic, urea increased, urinary retention, urticaria, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aripiprazole or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6297701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders (seizures have been rarely reported), in suicidal patients, patients with concomitant systemic illnesses, patients with unstable heart disease or a recent history of MI (these patients not adequately studied), and in those at risk of aspiration pneumonia (esophageal dysmotility and aspiration have been associated with antipsychotic agents). May cause orthostatic hypotension; use with caution in patients at risk for this effect or in those who would not tolerate transient hypotensive episodes (eg, cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension). May cause somnolence (dose-related). May cause alteration of temperature regulation (use with caution in patients exposed to temperature extremes).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Aripiprazole may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving aripiprazole; compare weight gain to standard growth curves.",
"     <b>",
"      Note:",
"     </b>",
"     A prospective, nonrandomized cohort study followed 338 antipsychotic na&iacute;ve pediatric patients (age: 4-19 years) for a median of 10.8 weeks (range: 10.5-11.2 weeks) and reported the following significant mean increases in weight in kg (and % change from baseline): Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). Increases in metabolic indices (eg, serum cholesterol, triglycerides, glucose) were also reported; however, these changes were not significant in patients receiving aripiprazole (Correll, 2009); additionally, in clinical trials, lipid changes observed with aripiprazole monotherapy in pediatric patients were similar to those observed with placebo. Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children and adolescents may experience a higher frequency of some adverse effects than adults, including EPS (20% vs 5%), fatigue (17% vs 8%), and somnolence (23% vs 6%).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains 400 mg fructose and 200 mg sucrose per mL. Orally disintegrating tablets contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aripiprazole is",
"     <b>",
"      not",
"     </b>",
"     FDA approved for the (adjunctive) treatment of depression in pediatric patients. Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment of depression (using antidepressants alone may induce manic episodes in patients with this condition).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause neuroleptic malignant syndrome (symptoms include hyperpyrexia, altered mental status, muscle rigidity, autonomic instability, acute renal failure, rhabdomyolysis, and elevated CPK). May cause extrapyramidal reactions, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hyperglycemia has been reported with atypical antipsychotics, which may be severe and include potentially fatal ketoacidosis or hyperosmolar coma; reports of hyperglycemia with aripiprazole therapy have been few and specific risk associated with this agent is not known. Use with caution and monitor glucose closely in patients with diabetes mellitus (or with risk factors such as family history or obesity); measure fasting blood glucose at the beginning of therapy and periodically during therapy in these patients; monitor for symptoms of hyperglycemia in all patients treated with aripiprazole; measure fasting blood glucose in patients who develop symptoms. Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients with schizophrenia, bipolar disorder, or irritability associated with autistic disorder. Medication therapy for pediatric patients with these disorders is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported with the use of aripiprazole in elderly patients with dementia-related psychosis. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Weak): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers: May decrease the serum concentration of ARIPiprazole. Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Weak): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: ARIPiprazole may enhance the adverse/toxic effect of DULoxetine. ARIPiprazole may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of ARIPiprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: May enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose adjustment is recommended, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F999024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A high-fat meal delays the time to peak plasma concentrations of aripiprazole by 3 hours and of dehydro-aripiprazole (active metabolite) by 12 hours. However, a high-fat meal does not affect peak concentrations or AUC of either compound.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aripiprazole demonstrated developmental toxicity and teratogenic effects in animal models. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. Information specific to the use of aripiprazole in pregnancy is limited. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers, 2009).  Healthcare providers are encouraged to enroll women 18-45 years of age exposed to aripiprazole during pregnancy in the Atypical Antipsychotics Pregnancy Registry (866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F999049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC with differential; fasting lipid profile and fasting blood glucose/Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); weight, growth, BMI, and waist circumference (especially in children), personal/family history of diabetes, blood pressure, mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F999027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aripiprazole is a quinolinone antipsychotic; its therapeutic effects may be mediated through a combination of partial agonist activity at D",
"     <sub>",
"      2",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors and antagonist activity at 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     receptors; it may cause orthostatic hypotension via its antagonist activity at adrenergic alpha",
"     <sub>",
"      1",
"     </sub>",
"     receptors. Aripiprazole exhibits high affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     , D",
"     <sub>",
"      3",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     receptors; moderate affinity for D",
"     <sub>",
"      4",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      7",
"     </sub>",
"     , alpha",
"     <sub>",
"      1",
"     </sub>",
"     adrenergic, and histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptors. It also possesses moderate affinity for the serotonin reuptake transporter; has no affinity for muscarinic (cholinergic) receptors. Aripiprazole functions as a partial agonist at the D",
"     <sub>",
"      2",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors, and as an antagonist at the 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     receptor.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F6298639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Initial: 1-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F999029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients 10-17 years of age, the pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole have been shown to be similar to adult values when adjusted for weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &ge;99%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2D6 and CYP3A4; the dehydro-aripiprazole metabolite has affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: 100%; Oral: Tablet: 87%;",
"     <b>",
"      Note:",
"     </b>",
"     Orally disintegrating tablets are bioequivalent to tablets; oral solution to tablet ratio of geometric mean for peak concentration is 122% and for AUC is 114%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CYP2D6 poor metabolizers:  Aripiprazole: 146 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: 1-3 hours; tablet: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (55%, ~18% of dose as unchanged drug); urine (25%, &lt;1% unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17350?source=see_link\">",
"      see \"Aripiprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of aripiprazole. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if patient feels more depressed, has thoughts of suicide, or becomes more agitated or irritable. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension, especially during initial dose titration (use caution when changing position from lying or sitting to standing).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Report the use of other medications, nonprescription medications, and herbal or natural products to physician and pharmacist; avoid alcohol and the herbal medicine, St John's wort. Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual muscle or skeletal movements), rapid heartbeat, severe dizziness, vision changes, skin rash, weight gain or loss, or worsening of condition to physician. If patient has diabetes, monitor blood glucose levels closely at beginning of therapy and periodically thereafter (may cause hyperglycemia). Patients may be more vulnerable to overheating and dehydration while taking this medication; maintain adequate hydration unless advised by prescriber to restrict fluids.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6297805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of aripiprazole should be periodically re-evaluated in patients receiving the drug for extended periods of time.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al, \"Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bastiaens L, \"A Non-Randomized, Open Study With Aripiprazole and Ziprasidone for the Treatment of Aggressive Behavior in Youth in a Community Clinic,\"",
"      <i>",
"       Community Ment Health J",
"      </i>",
"      , 2009, 45(1):73-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/18597173/pubmed\" id=\"18597173\" target=\"_blank\">",
"        18597173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Budman C, Coffey BJ, Shechter R, et al, \"Aripiprazole in Children and Adolescents With Tourette Disorder With and Without Explosive Outbursts,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008, 18(5):509-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/18928415/pubmed\" id=\"18928415\" target=\"_blank\">",
"        18928415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Correll CU, Manu P, Olshanskiy V, et al, \"Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(16):1765-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19861668/pubmed\" id=\"19861668\" target=\"_blank\">",
"        19861668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Kauffman R, Sallee FR, et al, \"An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents With Conduct Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(4):431-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19702495/pubmed\" id=\"19702495\" target=\"_blank\">",
"        19702495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Short EJ, Leskovec T, et al, \"Aripiprazole in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008, 18(4):347-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/18759644/pubmed\" id=\"18759644\" target=\"_blank\">",
"        18759644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcus RN, Owen R, Kamen L, et al, \"A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2009, 48(11):1110-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19797985/pubmed\" id=\"19797985\" target=\"_blank\">",
"        19797985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masi G, Cosenza A, Millepiedi S, et al, \"Aripiprazole Monotherapy in Children and Young Adolescents With Pervasive Developmental Disorders: A Retrospective Study,\"",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2009, 23(6):511-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19480469/pubmed\" id=\"19480469\" target=\"_blank\">",
"        19480469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy TK, Mutch PJ, Reid JM, et al, \"Open Label Aripiprazole in the Treatment of Youth With Tic Disorders,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(4):441-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19702496/pubmed\" id=\"19702496\" target=\"_blank\">",
"        19702496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owen R, Sikich L, Marcus RN, et al, \"Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(6):1533-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19948625/pubmed\" id=\"19948625\" target=\"_blank\">",
"        19948625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seo WS, Sung HM, Sea HS, et al, \"Aripiprazole Treatment of Children and Adolescents With Tourette Disorder or Chronic Tic Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008, 18(2):197-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/18439116 /pubmed\" id=\"18439116 \" target=\"_blank\">",
"        18439116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stigler KA, Diener JT, Kohn AE, et al, \"Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(3):265-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19519261/pubmed\" id=\"19519261\" target=\"_blank\">",
"        19519261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valicenti-McDermott MR and Demb H, \"Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents With Developmental Disabilities,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(5):549-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/17069544 /pubmed\" id=\"17069544 \" target=\"_blank\">",
"        17069544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, \"The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoo HK, Choi SH, Park S, et al, \"An Open-Label Study of the Efficacy and Tolerability of Aripiprazole for Children and Adolescents With Tic Disorders,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2007, 68(7):1088-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/17685747/pubmed\" id=\"17685747\" target=\"_blank\">",
"        17685747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoo HK, Lee JS, Paik KW, et al, \"Open-Label Study Comparing the Efficacy and Tolerability of Aripiprazole and Haloperidol in the Treatment of Pediatric Tic Disorders,\"",
"      <i>",
"       Eur Child Adolesc Psychiatry",
"      </i>",
"      , 2011, 20(3):127-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/35/7737/abstract-text/21188439/pubmed\" id=\"21188439\" target=\"_blank\">",
"        21188439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13180 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7737=[""].join("\n");
var outline_f7_35_7737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708627\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136801\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490633\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999002\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999039\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136774\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136761\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321186\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874282\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999025\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999003\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136826\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999009\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6297701\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999010\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136814\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136768\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999024\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136770\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136784\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999049\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999027\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6298639\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999029\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999053\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6297805\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=related_link\">",
"      Aripiprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17350?source=related_link\">",
"      Aripiprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_35_7738="Treatment of acute pancreatitis";
var content_f7_35_7738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7738/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7738/contributors\">",
"     Santhi Swaroop Vege, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7738/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/35/7738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/35/7738/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/35/7738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis can be divided into two broad categories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Edematous, interstitial, or mild acute pancreatitis",
"     </li>",
"     <li>",
"      Necrotizing or severe acute pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of acute pancreatitis is based upon the severity of the condition, as determined by the clinical, laboratory and a severity scoring system (",
"    <a class=\"graphic graphic_algorithm graphicRef66576 \" href=\"UTD.htm?31/58/32687\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    .) Treatment is aimed at correcting any underlying predisposing factors and at the pancreatic inflammation itself.",
"   </p>",
"   <p>",
"    Most attacks of acute pancreatitis are mild with recovery occurring within five to seven days. Death is unusual in such patients. In contrast, severe necrotizing pancreatitis is associated with a high rate of complications and significant mortality.",
"   </p>",
"   <p>",
"    A subgroup of patients with severe pancreatitis has early severe acute pancreatitis or fulminant acute pancreatitis characterized by extended pancreatic necrosis with organ failure either at admission or within 72 hours. Early severe acute pancreatitis or fulminant acute pancreatitis has a high mortality of 25 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intermediate group of patients with \"moderately severe acute pancreatitis\", comprised of patients with local complications but no organ failure, has also been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/5\">",
"     5",
"    </a>",
"    ]. Moderately severe acute pancreatitis has a low mortality like mild acute pancreatitis but morbidity (requiring prolonged hospital stay and interventions) similar to severe acute pancreatitis.",
"   </p>",
"   <p>",
"    This topic reviews the treatment of acute pancreatitis. Our recommendations are largely consistent with the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) guidelines for the treatment of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The etiology, clinical manifestations, diagnosis of acute pancreatitis, methods to predict its severity, and the diagnosis and management of pancreatic pseudocysts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446700317\">",
"    <span class=\"h1\">",
"     PRETREATMENT ASSESSMENT OF DISEASE SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in managing patients with acute pancreatitis is determining the severity. The severity of acute pancreatitis can be predicted based upon clinical, laboratory, and radiologic risk factors, severity grading systems, and serum markers. Some of these can be performed on admission to assist in triage of patients, while others can only be obtained after the first 48 to 72 hours or later. Although measurement of amylase and lipase are useful for diagnosis of pancreatitis, serial measurements in patients with acute pancreatitis are not useful to predict prognosis or for altering management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild acute pancreatitis is treated with supportive care including pain control, intravenous fluids, and correction of electrolyte and metabolic abnormalities. The majority of patients require no further therapy, and recover and eat within three to seven days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Pain management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Nutrition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In severe acute pancreatitis, intensive care unit monitoring and support of pulmonary, renal, circulatory, and hepatobiliary function may minimize systemic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs and urine output should be monitored every few hours in the first 24 to 48 hours. Patients with severe pancreatitis will need ongoing monitoring for other complications that might arise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"       \"Abdominal compartment syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sustained hypoxemia, hypotension refractory to a bolus of IV fluids, and possibly renal insufficiency that does not respond to a fluid bolus warrant prompt transfer to an intensive care unit for close monitoring.",
"     </li>",
"     <li>",
"      The importance of fluid replacement in the initial stages has been accepted as standard of care [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/9\">",
"       9",
"      </a>",
"      ]. Fluid replacement is important because patients with necrotizing pancreatitis develop vascular leak syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/10\">",
"       10",
"      </a>",
"      ]. At least one report suggested that inadequate fluid replacement (as evidenced by persistent hemoconcentration at 24 hours) was associated with development of necrotizing pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/11\">",
"       11",
"      </a>",
"      ]. Inadequate hydration can lead to hypotension and acute tubular necrosis. In addition, fluid depletion damages pancreatic microcirculation and results in further pancreatic necrosis. Faster initial hydration was associated with decreased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The exact amount and composition of fluid resuscitation that is required has not been extensively studied but several approaches have been published [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. After initial resuscitation with 20",
"      <span class=\"nowrap\">",
"       cc/kg",
"      </span>",
"      of intravenous fluid given over 60 to 90 minutes, approximately 250 to 300 cc of intravenous fluids per hour are typically required for 48 hours if the cardiac status permits [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/15\">",
"       15",
"      </a>",
"      ]. Adequate fluid replacement can be assessed by improvement in vital signs and urine output and reduction in hematocrit and blood urea nitrogen (BUN) over 24 hours, particularly if they were high at the onset. Monitoring the BUN may be particularly important, as both the BUN at the time of admission and the change in BUN during the first 24 hours of hospitalization predict mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/16\">",
"       16",
"      </a>",
"      ]. Increased fluid resuscitation should be considered in patients whose BUN levels stay the same or increase.",
"      <br/>",
"      <br/>",
"      Fluids should be titrated to maintain urine output greater than 0.5",
"      <span class=\"nowrap\">",
"       cc/kg/hour",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/17\">",
"       17",
"      </a>",
"      ]. However, a low urine output may reflect the development of acute tubular necrosis rather than persistent volume depletion. In this setting, aggressive fluid replacement can lead to peripheral and pulmonary edema without improving the urine output. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is some evidence that fluid resuscitation with lactated Ringer&rsquo;s solution may be superior to normal saline [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/18\">",
"       18",
"      </a>",
"      ]. In one small randomized trial of 40 patients, patients who received lactated Ringer&rsquo;s had significantly lower mean C-reactive protein levels compared with patients who received normal saline (52 versus 104",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and a significant reduction in systemic inflammatory response syndrome (SIRS) after 24 hours (84 versus 0 percent). However, in rare patients with acute pancreatitis due to hypercalcemia, lactated Ringer&rsquo;s is contraindicated because it contains 3",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      calcium. In these patients normal saline is the preferred fluid for volume resuscitation.",
"     </li>",
"     <li>",
"      Oxygen saturation needs to be assessed routinely and supplemental oxygen administered to maintain arterial oxygen saturation of greater than 95 percent. Blood gas analysis should be done if oxygen saturation is less than 95 percent or if clinical situation demands. Hypoxia may be due to splinting, atelectasis, pleural effusions, opening of intrapulmonary shunts, or acute respiratory distress syndrome (ARDS). Persistent or progressive hypoxia may require mechanical ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolytes should be monitored in patients with acute pancreatitis based on disease severity. Hypocalcemia should be corrected if ionized calcium is low or if there are signs of neuromuscular instability (Chvostek&rsquo;s or Trousseau&rsquo;s sign). Low magnesium levels may cause hypocalcemia and should be corrected.",
"     </li>",
"     <li>",
"      Serum glucose levels should be carefully monitored hourly in patients with severe pancreatitis and sliding scale insulin should be used to keep blood sugar levels under good control. Hyperglycemia may result from parenteral nutritional therapy, decreased insulin release, increased gluconeogenesis, and decreased glucose utilization, and may increase the risk of secondary pancreatic infections.",
"     </li>",
"     <li>",
"      Deep vein thrombosis prophylaxis should be considered in bedridden patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is often the dominant symptom. Patients with hypovolemia from vascular leak and hemoconcentration may have ischemic pain. Markers of ischemia include metabolic acidosis and elevated serum lactate. Uncontrolled pain can contribute to the hemodynamic instability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention to adequate fluid resuscitation should be the first priority in addressing severe abdominal pain (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Adequate pain control requires the use of intravenous opiates, usually in the form of a patient controlled analgesia pump. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"       \"Pain control in the critically ill adult patient\"",
"      </a>",
"      .)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      (intravenous) may be used for pain relief in acute pancreatitis. Fentanyl is being increasingly used due to its better safety profile, especially in renal impairment. As with other opiates, fentanyl can depress respiratory function. It can be given both as boluses as well as constant infusion. The typical dose for bolus regimen ranges from 20 to 50 micrograms with a 10-minute lock-out period (time from the end of one dose infusion to the time the machine starts responding to another demand). Patients on patient-controlled analgesia should be carefully monitored for side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link&amp;anchor=H4721198#H4721198\">",
"       \"Pain control in the critically ill adult patient\", section on 'Opioid side effects'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      has been favored over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      for analgesia in pancreatitis because studies showed that morphine caused an increase in sphincter of Oddi pressure. However, there are no clinical studies to suggest that morphine can aggravate or cause pancreatitis or cholecystitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/19\">",
"       19",
"      </a>",
"      ]. It is important to note that meperidine has a short half-life and repeated doses can lead to accumulation of the metabolite normeperidine that causes neuromuscular irritation and, rarely, seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild pancreatitis can often be managed with intravenous hydration alone since recovery often occurs rapidly, allowing patients to resume an oral diet within a week. Nutritional support is often required in patients with severe pancreatitis.",
"   </p>",
"   <p>",
"    Nutritional support should be provided to those who are unlikely to resume oral intake for more than five to seven days. Nasojejunal tube feeding (using an elemental or semi-elemental formula) is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    . Early enteral nutrition (24 to 48 hours) should be initiated upon transfer to an intensive care unit, development of organ dysfunction, or systemic inflammatory response syndrome (SIRS) persisting for 48 hours if severe acute pancreatitis is confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Enteral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral feeding is recommended in patients with severe acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A benefit of enteral nutrition is its ability to maintain the intestinal barrier and prevent bacterial translocation from the gut, which may be a major cause of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .) Another advantage is the avoidance of the complications associated with parenteral nutrition including catheter sepsis (which occurs in 2 percent even if the catheter is managed appropriately) and less frequent complications such as arterial laceration, pneumothorax, vein thrombosis, thrombophlebitis, and catheter embolism. In patients with a partial gastric outlet obstruction due to inflammation or a fluid collection, a few weeks of enteral feeding allows for the inflammation to subside or the fluid collection to mature and be drained, leading to resolution of the obstruction and resumption of oral feeding. Consistent with previous meta-analyses, a 2010 meta-analysis of eight trials demonstrated that enteral nutrition significantly reduced mortality, multiple organ failure, systemic infections, and the need for surgery compared with those who received parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiologic or endoscopic placement of a jejunal feeding tube beyond the ligament of Treitz and enteral feeding should be attempted. If this is not possible, nasogastric feeding has been proposed as an easier alternative. A controlled trial comparing nasogastric with nasojejunal feedings found no significant differences in APACHE II score, CRP measurement, pain levels, or analgesic requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/28\">",
"     28",
"    </a>",
"    ]. However, another small study comparing nasogastric feeding with TPN noted increased pulmonary and total complications in the nasogastric group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/29\">",
"     29",
"    </a>",
"    ]. Further studies are needed before the nasogastric approach can be recommended.",
"   </p>",
"   <p>",
"    We use high protein, low fat, semi-elemental feeding formulas (eg, Peptamen AF&reg;) because of a reduction in pancreatic digestive enzymes. We start at 25 cc per hour and advance as tolerated to at least 30 percent of the calculated daily requirement (25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    ideal body weight), even in the presence of ileus. Signs that the formula is not tolerated include gastric residual volumes &gt;400 cc (with nasogastric feeding), vomiting (with nasogastric feeding), bloating, or diarrhea (&gt;5 watery stools or &gt;500 mL per 24 hours with exclusion of",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin and medication-induced diarrhea) that resolves if the feeding is held.",
"   </p>",
"   <p>",
"    The presence of fluid collections or elevated pancreatic enzymes is not necessarily a contraindication to oral or enteral feeding. However, in a subgroup of patients there is clear correlation of pain, recurrence of pancreatitis, or worsening of fluid collections, with feeding, either oral or enteral. These patients often have disrupted pancreatic ducts with fluid collections. Drainage of fluid collections may allow resumption of oral intake. If the fluid collections are not considered suitable for drainage or if the target rate of enteral feeding is not achieved within 48 to 72 hours, supplemental parenteral nutrition should be provided. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Parenteral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Parenteral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral nutrition should be initiated in patients who do not tolerate enteral feeding. The use of parenteral nutrition as an adjunct to enteral nutrition to improve provision of calories and protein to critically ill patients may be harmful according to two studies. The first study was a multicenter trial that randomly assigned 4640 critically ill adults who were already receiving enteral nutrition to have supplemental parenteral nutrition initiated early (within 48 hours of ICU admission) or late (after the eighth day of ICU admission) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/30\">",
"     30",
"    </a>",
"    ]. Those who received early parenteral nutrition were more likely to develop a new infection and had a longer duration of mechanical ventilation, ICU stay, and hospitalization. The second study was an observational study that compared three groups: enteral nutrition alone, enteral nutrition plus early parenteral nutrition, and enteral nutrition plus late parenteral nutrition in mechanically ventilated critically ill adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/31\">",
"     31",
"    </a>",
"    ]. Enteral nutrition plus either early or late parenteral nutrition was associated with increased mortality compared with enteral nutrition alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link&amp;anchor=H935231#H935231\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Parenteral nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initiation of oral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;When to begin oral feedings depends on the severity of the pancreatitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mild pancreatitis, in the absence of ileus, nausea or vomiting, oral feeds can be initiated as soon as the pain starts improving and narcotic requirements are decreasing. This usually occurs 24 to 48 hours after the onset of pancreatitis. Traditionally, patients have been advanced from a clear liquid diet to solid food as tolerated. More recent data suggest that early refeeding when patients are subjectively hungry, regardless of resolution of abdominal pain and normalization of pancreatic enzymes, may be safe [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In addition, starting first with a solid, low fat diet may also be safe, although it does not necessarily decrease length of stay [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/32,34-36\">",
"       32,34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In moderate to severe pancreatitis, oral feeding is frequently not tolerated due to postprandial pain, nausea, or vomiting, probably related to gastroduodenal inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extrinsic compression from fluid collections leading to gastric outlet obstruction. Patients are generally placed on enteral or parenteral feeding as discussed above. When the local complications start improving, oral feeds are initiated and advanced as tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of pancreatic infection is a leading cause of morbidity and mortality in acute necrotizing pancreatitis. Approximately one-third of patients with pancreatic necrosis develop infected necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who develop infection tend to have more extensive necrosis. Although infection can occur early in the course of necrotizing pancreatitis, it is more often seen late in the clinical course (after 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The important organisms causing infection in necrotizing pancreatitis are predominantly gut-derived, including",
"    <em>",
"     Escherichia coli, Pseudomonas, Klebsiella,",
"    </em>",
"    and",
"    <em>",
"     Enterococcus",
"    </em>",
"    . The majority of infections (about 75 percent) are monomicrobial. Fungal infection and infection with gram-positive organisms are uncommon but occur more frequently in the setting of prophylactic antibiotic use for severe acute pancreatitis, especially when used for more than 10 to 14 days. Fungal infections occur in approximately 9 percent of necrotizing pancreatitis and it is not clear if they are associated with higher mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches taken to decrease bacterial infections in acute necrotizing pancreatitis include enteral feeding, systemic antibiotics, percutaneous computerized tomography (CT) guided aspiration, and necrosectomy. Our approach based upon these data is summarized in the following algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef66576 \" href=\"UTD.htm?31/58/32687\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Percutaneous CT-guided aspiration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Necrosectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this is still an area of debate, in the author's practice, we initiate antimicrobial therapy with",
"    <span class=\"nowrap\">",
"     imipenem/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"      meropenem",
"     </a>",
"    </span>",
"    and continue it for 7 to 10 days if there is necrotizing pancreatitis (involving more than approximately 30 percent of the pancreas). Because of the risk of fungal superinfection, antibiotics should be stopped after 7 to 10 days unless infection is documented. Given that the data are equivocal regarding a benefit to prophylactic antibiotics, it is also reasonable to withhold antibiotics until there is clinical evidence of infection (eg, fever, leukocytosis) or infection has been demonstrated after sampling the necrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6\">",
"     6",
"    </a>",
"    ]. We do not routinely recommend prophylactic antifungal therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Studies evaluating the benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/39-42\">",
"     39-42",
"    </a>",
"    ] and harms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/43-48\">",
"     43-48",
"    </a>",
"    ] of prophylactic antibiotics have produced disparate results. Contradictory results on the use of prophylactic antibiotics may be due to differences in methodological quality, inconsistent presence of organ failure in these studies, differences in antibiotic regimens and feeding used, and lack of data on adverse effects, making direct comparisons difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One systematic review concluded prophylactic antibiotics decreased mortality in severe pancreatitis, but not the rate of infected pancreatic necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a subsequent meta-analysis of seven trials detected no mortality benefit or reduction in the incidence of infected necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further casting doubt on the benefit of prophylactic antibiotics is recognition that it can be associated with the selection of resistant organisms and the development of fungal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/46-48\">",
"       46-48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines issued by multiple societies also differ in their recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Gastroenterology guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/6\">",
"       6",
"      </a>",
"      ] do not recommend prophylactic antibiotics.",
"     </li>",
"     <li>",
"      Guidelines from the American Gastroenterological Association [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/54\">",
"       54",
"      </a>",
"      ] do not make a firm recommendation with regard to prophylactic antibiotics, but note that: \"Antibiotic prophylaxis, if used, should be restricted to patients with substantial pancreatic necrosis (&gt;30 percent of the gland necrotic by CT criteria) and should continue for no more than 14 days.\"",
"     </li>",
"     <li>",
"      Guidelines from the Italian Association for the Study of the Pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/55\">",
"       55",
"      </a>",
"      ] recommend antibiotics for patients with CT-proven necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether there is a benefit to a specific class of antibiotics is also unclear. However, the authors suggest imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    for 14 days for patients with proven necrosis based on the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial, 60 patients with severe acute pancreatitis with necrosis affecting at least 50 percent of the pancreas were randomly assigned to receive two weeks of pefloxacin, 400 mg twice daily, or imipenem, 500 mg three times daily, within 120 hours of symptom onset. Rates of infected necrosis were significantly lower in patients treated with imipenem as compared with pefloxacin (10 and 34 percent, respectively), although mortality was not significantly different in the two groups. [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of five trials showed reduced sepsis and mortality but not a reduction in prevention of necrosis with antibiotics (imipenem or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/56\">",
"       56",
"      </a>",
"      ]. However, a subgroup of patients receiving prophylactic imipenem had reduction in infected necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Percutaneous CT-guided aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT-guided percutaneous aspiration with Gram's stain and culture is recommended when infected pancreatic necrosis is suspected (clinical instability or sepsis physiology, increasing white blood cell count, fevers) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Sterile necrosis does not usually require antibiotics and acute fluid collections do not require therapy in the absence of infection or obstruction of a surrounding hollow viscus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continued conservative management in a stable patient allows organization of necrotic fluid collections permitting a minimally invasive debridement either by endoscopic or percutaneous route to clear necrotic debris [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. However, if there has been no improvement after one week of empiric antibiotics in a patient with &gt;30 percent pancreatic necrosis and there are clinical signs of infection without another obvious site of infection, we perform a percutaneous CT-guided aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. We repeat percutaneous CT-guided aspiration if the conditions of probable infection remain and no other source is found.",
"   </p>",
"   <p>",
"    If there is evidence of a bacterial infection, we consider performing a necrosectomy (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Necrosectomy'",
"    </a>",
"    below) change the antibiotics according to the culture and sensitivity results (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73456 \" href=\"UTD.htm?18/22/18784\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/37,66\">",
"     37,66",
"    </a>",
"    ]. If the aspirated material is sterile, we continue conservative treatment for four to six weeks. A repeat aspiration in five to seven days may be indicated in patients with signs of systemic toxicity since a negative fine needle aspiration does not confidently exclude infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Necrosectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for necrosectomy include infected pancreatic necrosis and sterile symptomatic pancreatic necrosis with abdominal pain preventing oral intake. Surgical debridement of pancreatic necrosis (necrosectomy) can be accomplished by open surgery or a minimally invasive approach (endoscopic or percutaneous radiologic). In a randomized controlled trial, compared to open necrosectomy, a minimally invasive step-up approach consisting of percutaneous drainage followed, if necessary, by open necrosectomy, reduced the rate of the composite end point of major complications or death among patients with necrotizing pancreatitis and infected necrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38809?source=see_link\">",
"     \"Pancreatic debridement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1416798\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of protease inhibitors in the treatment of acute pancreatitis remains unclear as evidence from clinical trials and a meta-analysis show only marginal benefit in patients with severe pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/66,67,70-72\">",
"     66,67,70-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above treatment for pancreatic inflammation, treatment of acute pancreatitis is aimed at correcting any underlying predisposing factors, such as gallstones and hypertriglyceridemia, and treating complications such as splenic vein thrombosis and abdominal compartment syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gallstone pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone pancreatitis requires specific therapeutic considerations, in addition to the above recommendations. In this disorder, obstructive stones in the biliary tract or ampulla of Vater are responsible for the pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of gallstone pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Endoscopic retrograde cholangiopancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early endoscopic retrograde cholangiogram (ERCP) with papillotomy or surgical intervention to remove bile duct stones may lessen the severity of gallstone pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/73\">",
"     73",
"    </a>",
"    ]. Multiple studies suggest that early endoscopic papillotomy is of benefit in patients with acute biliary pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Endoscopic papillotomy is typically accompanied by placement of a plastic biliary stent to decrease the risk of post-ERCP pancreatitis, which can occur in a patient who already has gallstone pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link&amp;anchor=H7#H7\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\", section on 'Pancreatic sphincterotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, ERCP should be performed within 72 hours in those with a high suspicion of persistent bile duct stones (ie, visible common bile duct stone on noninvasive imaging, persistently dilated common bile duct, jaundice or rising liver chemistries) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of cholangitis or a high suspicion of a persistent common bile duct stone, early ERCP (within 24 to 48 hours) is controversial. Three meta-analyses and one multicenter study reached different conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. Two meta-analyses found that early ERCP in patients without cholangitis did not lead to a significant reduction in the risk of overall complications and mortality regardless of the predicted severity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/76,78\">",
"     76,78",
"    </a>",
"    ]. In another meta-analysis of five prospective randomized trials that included 702 patients, early ERCP reduced complications but not mortality in predicted severe pancreatitis; no benefit was observed in predicted mild pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest early ERCP should be performed within 24 to 48 hours if there is concomitant cholangitis, persistently abnormal liver tests, or increasing liver tests (indicating the presence of a stone in the common bile duct).",
"   </p>",
"   <p>",
"    In the absence of persistent bile duct stones, cholangitis, persistently abnormal liver tests, or increasing liver tests, patients with biliary pancreatitis, can undergo ERCP before the cholecystectomy.",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatogram (MRCP) to determine the need for ERCP should be considered in patients in whom the clinical course is not improving sufficiently to allow timely laparoscopic cholecystectomy and intraoperative cholangiogram, pregnant patients, patients with high risk of difficult ERCP (altered surgical anatomy or coagulopathy), or if there is intermediate concern regarding the possibility of a retained common bile duct stone, and the patient is not felt to be a good candidate for cholecystectomy with cholangiogram within the near future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy should be performed after recovery in all patients with gallstone pancreatitis. Failure to perform a cholecystectomy is associated with a 25 to 30 percent risk of recurrent acute pancreatitis, cholecystitis, or cholangitis within 6 to 18 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/79\">",
"     79",
"    </a>",
"    ]. The risk of recurrent pancreatitis is highest in patients who have not undergone a sphincterotomy.",
"   </p>",
"   <p>",
"    In patients who have had mild pancreatitis, cholecystectomy can usually be performed safely within seven days after recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/80\">",
"     80",
"    </a>",
"    ]. In a randomized prospective study of 50 patients with mild gallstone pancreatitis, laparoscopic cholecystectomy performed within 48 hours of admission resulted in a shorter hospitalized stay than one performed after resolution of pain and laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, in patients who have had severe necrotizing pancreatitis, delaying cholecystectomy for at least three weeks may be reasonable because of an increased risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/80\">",
"     80",
"    </a>",
"    ]. Cholecystectomy after sphincterotomy in elderly and sick patients is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link&amp;anchor=H7#H7\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\", section on 'Safety of outpatient sphincterotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the clinical suspicion of common bile duct stones is high (eg, in those with persistent or worsening liver test abnormalities or cholangitis), a preoperative ERCP is the best test as there is a high likelihood that therapeutic intervention (sphincterotomy, stone extraction) will be required (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Endoscopic retrograde cholangiopancreatography'",
"    </a>",
"    above). On the other hand, if the suspicion of persistent common bile duct stones is low (eg, if liver tests normalize), an intraoperative cholangiogram during cholecystectomy may be preferable to avoid the morbidity associated with ERCP. MRCP and EUS are other imaging options that can exclude common bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/83\">",
"     83",
"    </a>",
"    ]. A preoperative ERCP can then be performed only in those with stones or sludge in the common bile duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266287453\">",
"    <span class=\"h2\">",
"     Biliary sludge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with biliary sludge are asymptomatic. However, biliary sludge is commonly found in 20 to 40 percent of patients with acute pancreatitis with no other obvious cause. On ultrasound, sludge appears as a mobile, low-amplitude echo that layers in the most dependent part of the gallbladder and is not associated with shadowing. We recommend cholecystectomy in patients who have had an episode of pancreatitis and have biliary sludge because of the high risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/32,36\">",
"     32,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology of acute pancreatitis\", section on 'Biliary sludge and microlithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no randomized trials documenting that intervention in patients with pancreatitis and biliary sludge or microcrystals prevents further attacks of pancreatitis, two studies suggest that biliary sludge can lead to pancreatitis, and that these patients may benefit from intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study of 86 patients with acute pancreatitis of which 31 were idiopathic, 23 (74 percent) had either biliary sludge on ultrasonography (11 patients)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cholesterol monohydrate or calcium bilirubinate crystals on biliary microscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/85\">",
"       85",
"      </a>",
"      ]. Of the 21 patients in whom biliary sludge was the only finding (two patients also had dilated bile ducts when restudied), the 10 patients treated by cholecystectomy or papillotomy had fewer recurrences of acute pancreatitis during follow-up (up to seven years) than the 11 untreated patients.",
"     </li>",
"     <li>",
"      Another report evaluated the efficacy of biliary drainage in 51 patients recovering from an attack of acute \"idiopathic\" pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/84\">",
"       84",
"      </a>",
"      ]. Clusters of cholesterol monohydrate crystals, calcium bilirubinate granules,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      microspheroliths were found in 67 percent. Examination of the gallbladder bile at cholecystectomy or serial ultrasonography of the gallbladder for up to 12 months showed that 73 percent of the patients with unexplained pancreatitis had biliary sludge or microlithiasis. Dissolution of gallstones by ursodeoxycholic acid (UDCA) or cholecystectomy prevented further attacks, while those with a delay in surgery or failed UDCA therapy continued to have episodes of pancreatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypertriglyceridemic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hypertriglyceridemic pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31064?source=see_link\">",
"     \"Hypertriglyceridemia-induced acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417528\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a rare cause of acute pancreatitis. If present, treatment should be directed at normalizing serum calcium levels and determining the underlying etiology. It is important to note that Lactated Ringer&rsquo;s solution is contraindicated in patients with hypercalcemia because it contains 3",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of calcium and normal saline is the preferred fluid for volume resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Splenic vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic vein thrombosis is seen on imaging in up to 19 percent of patients with acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should focus on the underlying pancreatitis since the effective treatment may be associated with spontaneous resolution of the thrombosis. Anticoagulation may be needed if there is extension of the clot into the portal or superior mesenteric vein resulting in hepatic decompensation or compromise of bowel perfusion. However, this needs to be considered along with the theoretical possibility of hemorrhage into pancreatic necrosis or fluid collections.",
"   </p>",
"   <p>",
"    Complications such as variceal bleeding are uncommon (in contrast to chronic pancreatitis) and thus prophylactic splenectomy is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32536547\">",
"    <span class=\"h2\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pancreatitis are at increased risk for intraabdominal hypertension and abdominal compartment syndrome. Factors that can contribute to abdominal compartment syndrome in patients with acute pancreatitis include tissue edema from aggressive fluid resuscitation, peripancreatic inflammation, ascites, and ileus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/88\">",
"     88",
"    </a>",
"    ]. Abdominal compartment syndrome is a life threatening complication that results in visceral organ ischemia and tissue necrosis. Abdominal compartment syndrome occurs when intra-abdominal pressure rises above 21 mmHg. Patients in the ICU should be monitored for potential abdominal compartment syndrome with serial measures of urinary bladder pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients who develop abdominal compartment syndrome are critically ill and unable to communicate. The rare patient who is able to convey symptoms may complain of malaise, weakness, lightheadedness, dyspnea, abdominal bloating, or abdominal pain. Nearly all patients with abdominal compartment syndrome have a tensely distended abdomen. Progressive oliguria and increased ventilatory requirements are also common in patients with abdominal compartment syndrome. Other findings may include hypotension, tachycardia, an elevated jugular venous pressure, jugular venous distension, peripheral edema, abdominal tenderness, or acute pulmonary decompensation. There may also be evidence of hypoperfusion, including cool skin, obtundation, restlessness, or lactic acidosis.",
"   </p>",
"   <p>",
"    If abdominal compartment syndrome is confirmed, either percutaneous catheter-based or surgical decompression is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/35/7738/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H24#H24\">",
"     \"Abdominal compartment syndrome\", section on 'Surgical decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with severe pancreatitis who require surgical decompression, this typically requires midline laparotomy. Following decompressive laparotomy, temporary abdominal closure is used until the need for an open abdomen has resolved. The abdomen is then closed primarily, functionally, or using skin grafts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link&amp;anchor=H632146314#H632146314\">",
"     \"Management of the open abdomen in adults\", section on 'Temporary abdominal closure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=see_link\">",
"       \"Patient information: Pancreatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"       \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute pancreatitis can be divided into two broad categories: edematous, interstitial or mild acute pancreatitis and necrotizing or severe acute pancreatitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) Treatment varies depending on the severity of the condition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"       \"Predicting the severity of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mild pancreatitis is treated for several days with supportive care including pain control, intravenous fluids, correction of electrolyte and metabolic abnormalities, and nothing by mouth. The majority of patients require no further therapy, and recover and eat within three to seven days. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In severe pancreatitis, intensive care unit monitoring and support of pulmonary, renal, circulatory, and hepatobiliary function may minimize systemic sequelae. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain is often the dominant symptom. Adequate pain control requires the use of intravenous opiates, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , usually in the form of a patient controlled analgesia pump. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pain management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with mild pancreatitis, recovery generally occurs quickly, making it generally unnecessary to initiate supplemental nutrition. Soft diet can be started after resolution of pain. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initiation of oral feeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe pancreatitis, we recommend attempting to provide early enteral nutrition in the first 72 hours through a nasojejunal tube placed endoscopically or radiologically (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If the target rate is not achieved within 48-72 hours and if severe acute pancreatitis is not resolved, supplemental parenteral nutrition should be provided. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Enteral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The occurrence of pancreatic infection is a leading cause of morbidity and mortality in acute necrotizing pancreatitis. We suggest prophylactic imipenem or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      in patients with necrosis that involves more than 30 percent of the pancreas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, not all guidelines recommend the routine use of antibiotics and it is reasonable to withhold antibiotics unless there is clinical or microbiologic evidence of infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef66576 \" href=\"UTD.htm?31/58/32687\">",
"       algorithm 1",
"      </a>",
"      ), based upon clinical and CT findings, to direct percutaneous aspiration, antibiotic therapy, and minimally invasive or open surgical debridement as needed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with gallstone pancreatitis, we recommend early ERCP and sphincterotomy for those who have a high suspicion of cholestasis and those with cholangitis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Cholecystectomy should be performed after recovery in all patients with gallstone pancreatitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gallstone pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/1\">",
"      Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/2\">",
"      Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas 2001; 22:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/3\">",
"      Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg 2006; 93:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/4\">",
"      Buter A, Imrie CW, Carter CR, et al. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002; 89:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/5\">",
"      Vege SS, Gardner TB, Chari ST, et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include \"moderately severe acute pancreatitis\". Am J Gastroenterol 2009; 104:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/6\">",
"      Banks PA, Freeman ML, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/7\">",
"      Forsmark CE, Baillie J, AGA Institute Clinical Practice and Economics Committee, AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007; 132:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/8\">",
"      Johnson C, Charnley R, Rowlands B, et al. UK guidelines for the management of acute pancreatitis. Gut 2005; 54 Suppl 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/9\">",
"      Talukdar R, Swaroop Vege S. Early management of severe acute pancreatitis. Curr Gastroenterol Rep 2011; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/10\">",
"      Whitcomb DC, Muddana V, Langmead CJ, et al. Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany. Am J Gastroenterol 2010; 105:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/11\">",
"      Brown A, Baillargeon JD, Hughes MD, Banks PA. Can fluid resuscitation prevent pancreatic necrosis in severe acute pancreatitis? Pancreatology 2002; 2:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/12\">",
"      Gardner TB, Vege SS, Chari ST, et al. Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. Pancreatology 2009; 9:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/13\">",
"      Gardner TB, Vege SS, Pearson RK, Chari ST. Fluid resuscitation in acute pancreatitis. Clin Gastroenterol Hepatol 2008; 6:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/14\">",
"      Haydock MD, Mittal A, Wilms HR, et al. Fluid therapy in acute pancreatitis: anybody's guess. Ann Surg 2013; 257:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/15\">",
"      Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. Am J Gastroenterol 2004; 99:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/16\">",
"      Wu BU, Johannes RS, Sun X, et al. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. Gastroenterology 2009; 137:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/17\">",
"      Wu BU, Conwell DL. Acute pancreatitis part I: approach to early management. Clin Gastroenterol Hepatol 2010; 8:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/18\">",
"      Wu BU, Hwang JQ, Gardner TH, et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol 2011; 9:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/19\">",
"      Helm JF, Venu RP, Geenen JE, et al. Effects of morphine on the human sphincter of Oddi. Gut 1988; 29:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/20\">",
"      Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med 2009; 37:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/21\">",
"      Doig GS, Heighes PT, Simpson F, et al. Early enteral nutrition, provided within 24 h of injury or intensive care unit admission, significantly reduces mortality in critically ill patients: a meta-analysis of randomised controlled trials. Intensive Care Med 2009; 35:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/22\">",
"      Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/23\">",
"      Fang JC, Delegge MH. Enteral feeding in the critically ill: the role of the gastroenterologist. Am J Gastroenterol 2011; 106:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/24\">",
"      McClave SA, Chang WK, Dhaliwal R, Heyland DK. Nutrition support in acute pancreatitis: a systematic review of the literature. JPEN J Parenter Enteral Nutr 2006; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/25\">",
"      Petrov MS, Pylypchuk RD, Emelyanov NV. Systematic review: nutritional support in acute pancreatitis. Aliment Pharmacol Ther 2008; 28:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/26\">",
"      Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA. Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst Rev 2010; :CD002837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/27\">",
"      Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. BMJ 2004; 328:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/28\">",
"      Eatock FC, Chong P, Menezes N, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. Am J Gastroenterol 2005; 100:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/29\">",
"      Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. Ann Surg 2006; 244:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/30\">",
"      Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/31\">",
"      Kutsogiannis J, Alberda C, Gramlich L, et al. Early use of supplemental parenteral nutrition in critically ill patients: results of an international multicenter observational study. Crit Care Med 2011; 39:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/32\">",
"      Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. Clin Nutr 2007; 26:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/33\">",
"      Li J, Xue GJ, Liu YL, et al. Early oral refeeding wisdom in patients with mild acute pancreatitis. Pancreas 2013; 42:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/34\">",
"      Sathiaraj E, Murthy S, Mansard MJ, et al. Clinical trial: oral feeding with a soft diet compared with clear liquid diet as initial meal in mild acute pancreatitis. Aliment Pharmacol Ther 2008; 28:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/35\">",
"      Jacobson BC, Vander Vliet MB, Hughes MD, et al. A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis. Clin Gastroenterol Hepatol 2007; 5:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/36\">",
"      Moraes JM, Felga GE, Chebli LA, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization: results from a prospective, randomized, controlled, double-blind clinical trial. J Clin Gastroenterol 2010; 44:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/37\">",
"      Beger HG, Bittner R, Block S, B&uuml;chler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986; 91:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/38\">",
"      Bradley EL 3rd, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. Am J Surg 1991; 161:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/39\">",
"      Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: A meta-analysis. J Gastrointest Surg 1998; 2:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/40\">",
"      Manes G, Uomo I, Menchise A, et al. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. Am J Gastroenterol 2006; 101:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/41\">",
"      B&uuml;chler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992; 103:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/42\">",
"      Bassi C, Larvin M, Villatoro E. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2003; :CD002941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/43\">",
"      Bai Y, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol 2008; 103:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/44\">",
"      Isenmann R, R&uuml;nzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004; 126:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/45\">",
"      Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg 2007; 245:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/46\">",
"      Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999; 188:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/47\">",
"      Isenmann R, Schwarz M, Rau B, et al. Characteristics of infection with Candida species in patients with necrotizing pancreatitis. World J Surg 2002; 26:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/48\">",
"      Gloor B, M&uuml;ller CA, Worni M, et al. Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. Arch Surg 2001; 136:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/49\">",
"      Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/50\">",
"      Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/51\">",
"      Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/52\">",
"      Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998; 115:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/53\">",
"      Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006; :CD002941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/54\">",
"      American Gastroenterological Association (AGA) Institute on \"Management of Acute Pancreatits\" Clinical Practice and Economics Committee, AGA Institute Governing Board. AGA Institute medical position statement on acute pancreatitis. Gastroenterology 2007; 132:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/55\">",
"      Pezzilli R, Zerbi A, Di Carlo V, et al. Practical guidelines for acute pancreatitis. Pancreatology 2010; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/56\">",
"      Heinrich S, Sch&auml;fer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006; 243:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/57\">",
"      Walser EM, Nealon WH, Marroquin S, et al. Sterile fluid collections in acute pancreatitis: catheter drainage versus simple aspiration. Cardiovasc Intervent Radiol 2006; 29:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/58\">",
"      Mortel&eacute; KJ, Girshman J, Szejnfeld D, et al. CT-guided percutaneous catheter drainage of acute necrotizing pancreatitis: clinical experience and observations in patients with sterile and infected necrosis. AJR Am J Roentgenol 2009; 192:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/59\">",
"      Baron TH, Morgan DE. Endoscopic transgastric irrigation tube placement via PEG for debridement of organized pancreatic necrosis. Gastrointest Endosc 1999; 50:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/60\">",
"      Clancy TE, Ashley SW. Current management of necrotizing pancreatitis. Adv Surg 2002; 36:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/61\">",
"      Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc 2005; 61:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/62\">",
"      Seewald S, Groth S, Omar S, et al. Aggressive endoscopic therapy for pancreatic necrosis and pancreatic abscess: a new safe and effective treatment algorithm (videos). Gastrointest Endosc 2005; 62:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/63\">",
"      Rodriguez JR, Razo AO, Targarona J, et al. Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. Ann Surg 2008; 247:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/64\">",
"      Gerzof SG, Banks PA, Robbins AH, et al. Early diagnosis of pancreatic infection by computed tomography-guided aspiration. Gastroenterology 1987; 93:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/65\">",
"      Freeny PC, Hauptmann E, Althaus SJ, et al. Percutaneous CT-guided catheter drainage of infected acute necrotizing pancreatitis: techniques and results. AJR Am J Roentgenol 1998; 170:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/66\">",
"      Yasuda T, Ueda T, Takeyama Y, et al. Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis. J Gastroenterol 2007; 42:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/67\">",
"      Morimoto A, Imamura T, Ishii R, et al. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer 2008; 113:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/68\">",
"      van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010; 362:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/69\">",
"      Freeman ML, Werner J, van Santvoort HC, et al. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas 2012; 41:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/70\">",
"      Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/71\">",
"      Imaizumi H, Kida M, Nishimaki H, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004; 28:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/72\">",
"      Seta T, Noguchi Y, Shimada T, et al. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 2004; 16:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/73\">",
"      R&uuml;nzi M, Saluja A, Lerch MM, et al. Early ductal decompression prevents the progression of biliary pancreatitis: an experimental study in the opossum. Gastroenterology 1993; 105:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/74\">",
"      Fan ST, Lai EC, Mok FP, et al. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med 1993; 328:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/75\">",
"      van Santvoort HC, Besselink MG, de Vries AC, et al. Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis: a prospective multicenter study. Ann Surg 2009; 250:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/76\">",
"      Petrov MS, van Santvoort HC, Besselink MG, et al. Early endoscopic retrograde cholangiopancreatography versus conservative management in acute biliary pancreatitis without cholangitis: a meta-analysis of randomized trials. Ann Surg 2008; 247:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/77\">",
"      Moretti A, Papi C, Aratari A, et al. Is early endoscopic retrograde cholangiopancreatography useful in the management of acute biliary pancreatitis? A meta-analysis of randomized controlled trials. Dig Liver Dis 2008; 40:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/78\">",
"      Tse F, Yuan Y. Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis. Cochrane Database Syst Rev 2012; 5:CD009779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/79\">",
"      Hernandez V, Pascual I, Almela P, et al. Recurrence of acute gallstone pancreatitis and relationship with cholecystectomy or endoscopic sphincterotomy. Am J Gastroenterol 2004; 99:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/80\">",
"      Uhl W, M&uuml;ller CA, Kr&auml;henb&uuml;hl L, et al. Acute gallstone pancreatitis: timing of laparoscopic cholecystectomy in mild and severe disease. Surg Endosc 1999; 13:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/81\">",
"      Aboulian A, Chan T, Yaghoubian A, et al. Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis: a randomized prospective study. Ann Surg 2010; 251:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/82\">",
"      Laws HL, Kent RB 3rd. Acute pancreatitis: management of complicating infection. Am Surg 2000; 66:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/83\">",
"      Calvo MM, Bujanda L, Calder&oacute;n A, et al. Role of magnetic resonance cholangiopancreatography in patients with suspected choledocholithiasis. Mayo Clin Proc 2002; 77:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/84\">",
"      Ros E, Navarro S, Bru C, et al. Occult microlithiasis in 'idiopathic' acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology 1991; 101:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/85\">",
"      Lee SP, Nicholls JF, Park HZ. Biliary sludge as a cause of acute pancreatitis. N Engl J Med 1992; 326:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/86\">",
"      Mortel&eacute; KJ, Mergo PJ, Taylor HM, et al. Splenic and perisplenic involvement in acute pancreatitis: determination of prevalence and morphologic helical CT features. J Comput Assist Tomogr 2001; 25:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/87\">",
"      Heider TR, Azeem S, Galanko JA, Behrns KE. The natural history of pancreatitis-induced splenic vein thrombosis. Ann Surg 2004; 239:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/88\">",
"      Radenkovic DV, Bajec D, Ivancevic N, et al. Decompressive laparotomy with temporary abdominal closure versus percutaneous puncture with placement of abdominal catheter in patients with abdominal compartment syndrome during acute pancreatitis: background and design of multicenter, randomised, controlled study. BMC Surg 2010; 10:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/89\">",
"      De Waele JJ, De Laet I, Kirkpatrick AW, Hoste E. Intra-abdominal Hypertension and Abdominal Compartment Syndrome. Am J Kidney Dis 2011; 57:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/35/7738/abstract/90\">",
"      Cheatham ML, Malbrain ML, Kirkpatrick A, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. II. Recommendations. Intensive Care Med 2007; 33:951.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5633 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7738=[""].join("\n");
var outline_f7_35_7738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H446700317\">",
"      PRETREATMENT ASSESSMENT OF DISEASE SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Enteral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Parenteral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initiation of oral feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Percutaneous CT-guided aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Necrosectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1416798\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gallstone pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Endoscopic retrograde cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266287453\">",
"      Biliary sludge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypertriglyceridemic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1417528\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Splenic vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32536547\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5633|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/58/32687\" title=\"algorithm 1\">",
"      Management algorithm for severe acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5633|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/22/18784\" title=\"diagnostic image 1\">",
"      Pancreatic abscess CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31064?source=related_link\">",
"      Hypertriglyceridemia-induced acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=related_link\">",
"      Management of the open abdomen in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38809?source=related_link\">",
"      Pancreatic debridement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=related_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=related_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=related_link\">",
"      Predicting the severity of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_35_7739="Echo for MI complications";
var content_f7_35_7739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanical complications of myocardial infarction recognized by two dimensional echocardiography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracavitary thrombus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cardiac rupture (cardiorrhexis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Contained rupture (pseudoaneurysm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Free wall rupture with tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillary muscle rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricular infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial effusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7739=[""].join("\n");
var outline_f7_35_7739=null;
var title_f7_35_7740="Three common porphyrias";
var content_f7_35_7740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The three most common porphyrias and their contrasting presentations, exacerbating factors, and approaches to diagnosis and treatment; PCT and AIP share features with some less common porphyrias (see footnotes)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presenting symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exacerbating factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most important screening tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyria cutanea tarda (PCT)",
"       </td>",
"       <td>",
"        Chronic, blistering skin lesions*",
"       </td>",
"       <td>",
"        Iron; alcohol; smoking; estrogens; hepatitis C; HIV; halogenated hydrocarbons",
"       </td>",
"       <td>",
"        Plasma or urine porphyrins",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Phlebotomy; low-dose hydroxychloroquine or chloroquine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute intermittent porphyria (AIP)",
"       </td>",
"       <td>",
"        Neurovisceral",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Drugs (mostly cytochrome P450-inducers); progesterone; dietary restrictions",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Urinary porphobilinogen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Hemin; glucose",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythropoietic protoporphyria (EPP)",
"       </td>",
"       <td>",
"        Acute, nonblistering skin photosensitivity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Erythrocyte protoporphyrin (total or free)",
"       </td>",
"       <td>",
"        &beta;-carotene",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also may occur in&nbsp;variegate porphyria&nbsp;and less commonly in hereditary coproporphyria; much more severe in&nbsp;congenital erythropoietic porphyria and hepatoerythropoietic porphyria.",
"     <br>",
"      &bull; Also useful for diagnosis of variegate porphyria, congenital erythropoietic porphyria, and hepatoerythropoietic porphyria.",
"      <br>",
"       &Delta; Features shared with hereditary coproporphyria,&nbsp;variegate porphyria and ALA dehydratase porphyria.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Karl Anderson, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7740=[""].join("\n");
var outline_f7_35_7740=null;
var title_f7_35_7741="Use of the varicella vaccine";
var content_f7_35_7741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the use of the varicella vaccine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persons &lt;13 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Varicella vaccine has been approved",
"for use among all healthy children between 12 months and 12 years of age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        12 to 18 months of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All children should be vaccinated routinely at 12 to 18",
"months of age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Varicella vaccine should optimally",
"be administered to a child at the same time as the MMR vaccine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        19 months to 12 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Proof of varicella vaccination or",
"natural infection should be provided before entry into child care or elementary school.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Varicella vaccine is recommended for",
"all children by their 13th birthday; proof of vaccination or natural infection",
"should also be considered for children entering middle school.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persons &ge;13 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella vaccine is approved for use among healthy",
"adolescents and adults.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Persons &gt;13 years should",
"receive two 0.5 mL doses of vaccine subcutaneously, four to eight weeks apart.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High-risk groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Persons who live or work in settings",
"where transmission of VZV is probable (eg, teachers of young children, day care",
"workers, employees of residential care institutions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons who live or work in settings where transmission",
"of VZV can occur (eg, college students, inmates and employees of correctional",
"facilities, military personnel)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Women of childbearing age who are not pregnant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adolescents and adults living in households with",
"children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        International travelers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Health care workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Household contacts of",
"immunocompromised persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Immunocompromised hosts are at high",
"risk (30 percent) for disseminated varicella.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Vaccination of healthy household",
"contacts protects immunocompromised patients by decreasing the likelihood of",
"introduction of wild-type virus into the household.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunosuppressed hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The varicella vaccine is",
"        <strong>",
"         not",
"        </strong>",
"        approved for persons with any underlying malignancy including blood dyscrasias,",
"lymphoma, leukemia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella vaccine is",
"        <strong>",
"         not",
"        </strong>",
"        currently approved for patients with HIV-infection; the use of varicella vaccine in HIV-infected",
"children is being evaluated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella vaccine is",
"        <strong>",
"         not",
"        </strong>",
"        approved for patients with cellular immunodeficiencies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Children/adolescents between the ages of 12 months and 17 years who have acute lymphocytic leukemia (ALL) in remission for at least 12 continuous months, peripheral lymphocyte count &gt;700/mm3, and have a platelet count &gt;100,000/mm3 within 24 hours of vaccination may obtain varicella vaccine through a research protocol.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the Centers for Disease Control and Prevention. Prevention of varicella: Update recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 1999; 48 (RR-6):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7741=[""].join("\n");
var outline_f7_35_7741=null;
var title_f7_35_7742="Serologic markers HBV";
var content_f7_35_7742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60627%7EGAST%2F60827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60627%7EGAST%2F60827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serologic markers for the different phases of acute and chronic hepatitis B virus infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HBsAg",
"       </td>",
"       <td class=\"subtitle1\">",
"        HBeAg",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgM anti-HBc",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG anti-HBc",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anti- HBs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anti- HBe",
"       </td>",
"       <td class=\"subtitle1\">",
"        HBV DNA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Acute HBV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        Early phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Window phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Recovery phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Chronic HBV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        Replicative phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Low, nonreplicative phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Flare of chronic HBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        Precore/core promoter mutants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        &nbsp;-",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;-",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Occult HBV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of the hepatitis B serologic panel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Results",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Susceptible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Immune due to natural infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Immune due to hepatitis B vaccination*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td rowspan=\"4\">",
"        Acutely infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td rowspan=\"4\">",
"        Chronically infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Four interpretations possible",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibody response (anti-HBs) can be measured quantitatively or qualitatively. A protective antibody response is reported quantitatively as 10 or more milliinternational units (&gt;=10 mIU/mL) or qualitatively as positive. Post-vaccination testing should be completed 1-2 months after the third vaccine dose for results to be meaningful.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Four interpretations:",
"     <br/>",
"     1. Might be recovering from acute HBV infection.",
"     <br/>",
"     2. Might be distantly immune and test not sensitive enough to detect very low level of anti-HBs in serum.",
"     <br/>",
"     3. Might be susceptible with a false positive anti-HBc.",
"     <br/>",
"     4. Might be undetectable level of HBsAg present in the serum and the person is actually chronically infected.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Centers for Disease Control and Prevention, Hepatitis B information for health professionals: Interpretation of hepatitis B serologic test results. Available from the CDC website.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7742=[""].join("\n");
var outline_f7_35_7742=null;
var title_f7_35_7743="Circadian pattern AMI SCD";
var content_f7_35_7743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Circadian pattern of nonfatal myocardial infarction and sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 526px; background-image: url(data:image/gif;base64,R0lGODlh6QEOAtUAAP///2aZmf+ZAICAgAAAAAAzZjNMTACZM39MADMzM4iIiH9/f8zMzHd3dxEREe7u7qqqqlVVVSIiIgAZM0RERABMGcDAwJmZmWZmZt3d3UBAQLu7uz8mABkmJkxycr9yAAAMGQAmDL+/vyAgID8/P6CgoGBgYB8TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADpAQ4CAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzL0WA9DR0tPU1dbX2Nna29zd3t/g4eLj5NMWzZgDJAvs7e7v8PHy8/T19vf4+fr7/P3+/wDbkRiA7tKABQVjLSCYkNLBhq8WQpz0cCIriRYhVcyYCiPHRhs/mvIoUlHIkqNIojx0ciUolS4JtSQigp6IQwoINDCDgQAB/waAHlAg4EAOzJiCZg5ZEKKC06dOQyAswsCnVQhiHhB10oCAAiI5d5LZQCCCGAhlpXT9eiQn2ygOCDwAsDbLUaSAlApZUOGA379+K0wlUjWBn7Bl0IoF1BWrlLhzudzF60cvAL6AAQs2UpjIUAVkEzxgMNTn6NIUMgi1qmC1z7cAHBTtSiGu2QcRrroFcMFn3J0XJPg0S9u2kJw+G+D2KcGxENfNq/o0PCRB2ddDRdNlvT2CgwbF01aNoNXBUAdAIQiPS/241/LnGSDXOb85fLnBp+dOvvtC3LRoJWCddl0NV8RklPFhGWaZBTbYENJZNZd1DkiQAQASoDdEhg/0hv9BVxgMAeIRsm33VVwM5PaWW1VJAEBYnfV0QV0o5mSWELlBkAEBLg6R4wMcIkaEdRuQ5aKMiA0FQYE60fjTeOW9mJZwDHQ2hFtR2ghAjmARQIFWVhUWWWxySalAZ2GhRQEAnwWIBIIJ6rFgXw0esBlVBLQnBFpeAWCln1ZNx4BwRFVJqIZDlFiXdQxAdqVXaJkV1nzJLfoTl0L8J2GiZVoHgZDVPZmniVx2BV6fJgLAKJRbRVpVUX+aGWWkWxKAFQSl5RmllIuROZdbiAVI61quoboUQ3EGMmeddj4oRKwPJFChAxdmCJQQGV5YxIhCcJvpbH0yquKjoI0K46gihvv/k5Y4EnDBET8GqVMRq466VpK21pVqveS1mpZsD4TWZWv+msVlXBuIuRWg2mVKwIUsmqvTsMai1eOxySbl7IF0NngnYYHaOtQFRp4mIWlWRbCflxmsnBoRiqrLwHI+fdpngdYBR6hXlgI1n3IrFzWEawlgBaoQ9RpWV4EOfKVvz6wWRat/eaLrHsFSp8UlcgPuyhuhhiHXQH//hUixAvMVfSCyGVe2MREMevz2SjmFSAicbdexbJ0fu8Tkl4Xgnfcce8s9+CCCHw7Hgk1B9ZRUigeS+BsrfwXmVX5al1bmBgLg2svFWFbTPDdF/sfkbkRwIZFgjomhAw8gJu9OOcYq/4xlpi+COhyeXj5vZ4UBP6qjjhKDe+6J7O7GUBcj7S6thUGv68LFP0PNObkcj/whyq8xaKHbeiV8AuP7aj4A1kOjgQYDYI+L9tsHzjYe0pG/542Mvh77vLPXCoHAR4AGL+AXP8TN7w4RGk4GCCWBd3FucwzQ3I0+py0jCHAXBCyg5A4YigvqIoMaPB0HQeHB7M0thIbonkNGSAsQopAPKqQIC2fhwhfqIYZRQJtQbiSnGcqihjbEAw6hIAEF7Ac2dyjh+04IgNHJo3R0OFoW8peF7/FwCasR2ieG6AStQEBAGNBTEn0YiwVxAAFoTCMaObCxBNpKC7Zry7y4QEUsDP/lWnvanBF285gy6SuFZNTCd5okRjso8RYLQoAAFsnIRSKgjVbbQhz3OMct1PEK1nHdEhozheIpgotO6ImtEnDFMQ6QiQtQZCMZ+UjORPIzoYlW1d6IMpZ9bTqagkAtX9YbolRyO7VJi5MYECDrUAA5X7HOft61ywwUU08R9ElqVuac8ajqOl75WX2wokxb1dJLVhlbn6iWlvtoiEmlfAMomxC7CzygAXjEwyFtkchVshKSgZoQUSx0TQZkoEQc8pCYnoWugBIAAy3iFRGGOUw1scldO3IRox4AUNh5iE+R5JDAPAkosxCJLEXBlHvWpDlbWYtTvxKfxJSzFRu5yQ7/6wRJIF9RT3sKoJV4EiOf2JI/FIUsAaASXqCKlpaj9ayhWrNVlHr6k5/SCmSGaR1HrTnRrXAJV1YxTP5i5ShgzStAsypLsZCozpliIXbgGdse5lmLmtoTp1AlQrSmtbqfGOl1FRwooHqUrSEIzKgyMxWZiJlUCCzVrjzC6xCeSgSNDq9MEEpLVUP6RoR1hoondRjEVBo2nYSVhxajQ0yXkKtImhKDqFTlW/F5lZGVjEI8Aso3zZKfUe1Hl7kiznR+2bMFeglFtPrRVkoqAdnmlrEQ0tzLpirZn0Rpa7vV6k+elav90WecZfNcwdLmnDiMNglaKRoE/rdWs64hfeX4/4b7pODWVcI1CpcMol3Ma4UE9Kq8cmqc4/bL3/76FyohoC8R2tvI90IhvvK9wneTgAEJpJWsehMwGgbQMWZZ+MIYroCEhUDgeybYKBuWQklNa8gQl4HCGE6xijOj4SqYUY1qZOOHvWtiKGxgvOPdAH7zgOIV+zjDIRadTWYMhwUjoVHT0WSJ5VThHztZM0FmIpH3YOQjSMDBGHBAOiPM5Cd7GcoulvKU81DlInixW4VUQuWEQE62RBOCEnwOaipowRqPocdf9nKLqQDEMZfVDBKIAAQuQEooqO6aCbPtG/vXv9qReAhslQOe8+zkPU+hz35uQ5mLMB9EwddWiDmXYf+CN6rOEA+yde4ypZ9safaKOdN12HQRNjA2Oj+BealKk3jyJD3RUA/V6F1f++TZ5FWruNVRUEdAls3sZjv72dCOtrTvMRA+fE9DodbJ+Mp36jEFm33rpcOkjX3sEKM3vehOt7rXze52u/vd0Aj3FxqQAQWkVa1OqN+1OqMk/ckOdojJEQADaGcxjJvcQIY1L7w44jQfOWS0/Y+b4/zACc45CZGOw8ERbmFkK/wWht2AAnDsQB4XPAwb5zjfTv7xUdgXzTsmtsrL3XJdbEBaEhCQAxxOOJZ/IeUzB3PNcYFR35Rcnj73AtCDHpikD50TD8BAa5R8WpkzveNOf/omGrD/pggevepJLPbV/+JxrcuiaTjiuaSzvoWlM73sZn/Fmemido2zXQtuDzrc4+4KAV3AP3YzuarH7rG7850SvSSKrZfMY7ETfu+HZwUDaq0gw2Mh7zOHfORTgYHAV37whBf65mERgbqL2/JXwLzKNT96UyjgO+CB8OlBH/qmP+Hc8DZH6+nQ8JiHvfYsNusAzgjj4hv/+MiHMQdQv/sn3BjHOu4h7WvPekir1qbYz772C8z85j/hAeD/fOOBL3omDOD620+/+m/afe8v4fVZ9b0hHT/26nMY/evPv00R0H73J+HKeaJl8qc39Hd19gcA56d/Coh9/Od/bqAVORF1WzZ7/+NHfrbnBAm4gBrISmaFe7kXDfIGawzXAKU3gOJWgG8nfPi3gfnXgBhIfMkXgzJYfMundaRUIJ7nBGQxQSGDFW92Iz8oZ9K0eBzWf+yFgnqngiy4gS7YBBm4hArYhB9Hb1cie0pAca3TWADHP1tIO970aAhohMmmX/9VhmboOCHAPvEmBB44ABrAAR+wSB+QfHEoAHOIfHV4h8ZXg+iDDecwfHQoh4Foh4MohSI4SvcVBdakXeHEMAzDbWXCUZDmQ224hn14DdhTicPWh+szAj5xAhwAgzM4isfHAWq4iW34hnk4iHpofKtYigyhiX8oisX3isdni67oSGK4EtOSc/9gJAWLOCTPs2tEZRYKIzTVIw3CVg2Z6Ids6IyXaA3NWAIW8AwrCIXbZ4hK8ITYuH7aiHHX2I0MuIsoAX9DBYx6lC5nUmp5AolzkYzRsIzXo3HhKI5vpYT2qH7fiATcmI/Zt4+ZJnXgR3VMsIgQgD/TxWhd6D8DVwQZtzj16I+6+AT9KJH3SJERKZEA6WdoFXufFia+xSMOFIQVJ4S2RHBykpH+uJEOqZL5yJID5pL2CJNEVlqm9wYPiZMyKY40eX8WqX09iYA72Y1BKV/hBX0mSDhDiY1BWZE/yYEY+ZTjaIOJKHg8tpRQ2JRYuYRaKZX7R44r0WAPlpSStpUs2JX/Xule+JiWUPl0vScnp/iB0hCC/GiWTLiWbMl+UZmXE/l0z5dja0WLpDiYyoeXbImWfImYeVmUDnhndqmBinmYhpmWkUmZYCkS9GZvY5mSfNmXTviYC1iZXimaUsmYKMRw58iZnUmaT8maP+maFmmaKBRyOEZeqpmYkzmauVmau9mal9mYMdmZeomBoBmFvfmaxxmbvwmcPrmayamRz7mS0fmSy5kRVJgXxal/sAmde4mb3bmY1TkRI/gHTsmb3ymZ52mZ6ambQ9eLApIAOWhI2dmC0zmT9cmT90mU4TkR5hh/twme62mexCmc2ymdWieQ4bdW8+mN+cmUDZqVD8qV//vJEbapoAQaoWeJoXcZoL6pdUimKxbqnByKnCOqnCXKnU93ZQ2QZROoBDs4BG32LBRHkhRUlxd6ogY6oCKqo945dHPXADcpjBCkaFihkPvjhboEhuXZoTwKoE2Knk+qnikqaITWokmwiNkGT+xIPltqPpLYnD36mTcapexJpgI6dJ0WT/m2OXWha8bIa8S4K18qlGMqpjtqp2FqfguqjxNqEbSmAERYkJuTpdvWpd0WQHuafgVKnTjKqGbKpMyJJ0A4Kv1mpAFnKwMXbImajRoKmZ0amp9qnJFKL4ECFDFakqhao88Yj5sKlKGqna9Kn41qn6PqBktKoo+Kq3jqpP+7CqW1uga3aqK5Kqy9KqXFWqZD13nk2ar/GKsMOqv4Ca36qXUlWBnMOpXDiqLHeqZ6Wqc193qbeZXeugTBqq3deqfnmqct95biiq7keq1fKa0OKq8QqnUiV5shqq7bCK8Xma05uq2Q+q01A5/5yqvparDvOq77qrAKl3PNAaQF66sHK7EJ664La7GH+EUQEEYRa6wT67EVq6/gyLCwJgFh1AAOEJ96w69qSa8S6rIZCrMb+nSJRy0di6wfi7Mhi7AXK7IK96eBKm4sy30y66lFC6pHK6paNyOAqiBD25YAq6s5y607S7EfJ0rg859WO7IYa6Ndi6gky5FlMWjmcbP/VNuzPMu1Pgu2X+tnzQFzWguyaLu1Xru2FvS0njmFXEcB4EEBaxK3Oju3cqu2aVu3hTtlvuOf7Wq3LRm2d+u4jdu2RFabSAm4Z0u4dMu2jBuckvurKIe3wxm1xDq1AVu1gwtruPKeKiu0kMu5m2t9rQu7nUtkmgKGXdSDvCFxMto5JGm4mfu4swumhwu8rztjKTuQV5CFBGUYXGKpvxS5xUunwSu90Vuu//qtFFC5VOA7O0GoW1o+vnu6mju80Eu+rmu+RIa1tvtpM9InbsowvUYEmhq7wvu75Wu/54u/MxZe4XoF9zIvovaIXToE8zu91uuoomuuphu4CkcBqysF/wfpPFVCqYu2kP0TvgyMwZerwaUruBmcad6hulYQkg3EZrqLqr07vvpbv+JLvOjLwh/sZ+wqT6C7qLTqrwhMulJbcwNJkKxrwDXsrHyatLCqdZrpkZbbwZjbwvfLxPnrxEQ2w0kUxEQsqzh8wwl8vS33l2iXxDvswRuswlAMw2H8cQnwt4v7wtSrxgeMxTo8ui2nmT0RpG3QxtF6xXecxTm8wGU8ZiP2dfJJv2u8woM8xoUcw2P2l2o6xYJsx9OKx4+sx26scEtyb/iWxoTsyPMKyZssyXk8hSGzvvTYyFTMyfVqyi9bc870KethhWVJyrAMxIKcYPB3aGarxBz8xf9LjMhPzMsfFk1q0weafMqeHMlvrMBgjMtjhjMi7MVwnMy6nMvPvMt9PGNMorg0HMvVW8rF3Mkt18MJ6szITM3K7MKZzM2eO2HozMfl3MS+TMbtnM4/t87QPM3SPM73rMXy/ASnisox688z283EfMz6vM+CyrxvBNBGq9BIy9BKK9CpbNBPkKVV/KwOXcQXbcUQ/c8SzRXu+7z1jM9i/M6HXJomUI0ondIqbQEmQM8dnQQUnQTBJpiEWdMcMALrk9M6vdMaMAI0XdODyQGhPNSB8tNAPYo3zdNK3YlGfdQyyIcvfdAP1V1GoIlyCQ3UuNJabQElcNXz6ARW/W50eQT/Ye1uYx3VRdDPaL3WbN3Wbv3WcB3Xcj3XdF3Xdn3XeJ3Xer3XfD0HZe3VgB3Ygg0OZ93XZ+CGg53Yir3Y28A+hr04fWoMOfnYdxbZoWPZdz3Z26PZlA0GnJ07n93ZXRDakUPaoo13mA0GUhQGorTIkH3awFpjbkTVXeA1m2QsCjUW6egFyEWRqV3Xph1XfbDaX6AYSAfbahDckaUnsKQr32QyLDNWYwUz4BJMt0FN/eEb81JbumXd7pEcNPO2Q1Ma0YHN3eQV2TEXTOI0ZQF7v7Vr/WIe4KMeviRGyo3cfHZAsogn+XRNFVItnmZQH3JQ6aKyMXMil2IsEeMiASwj/8PELv4TUUQQLwspjEWSWEgyL0rCJKeC4BMc31JiFlRiO/eN3+x1QAMAAhOw4iy+4iAwP7azU45IUEP1PYVi454WG+CSTD/hSW5BK5MSMh3eTyJVu6jmKJ4iRUlDKm9kKk8jM1EDAK6yFST+23R9SAMwAQWw5Vy+5RMA45E0V32VWYoVPoHnLTq+Lwm+Il7xV9oWST0D4bkByP4DJBUeKhOsNNmk4fmCKlAjVgWj4wFjWiVu4lCA5Vre5Vz+5fzdWu5SMs89Wy7TMlYBOt+i5jOD3TezWzrDGj0jJeAdNHJVGmqj5KKi5+xNFOzNFn8O4lPDHoRu5XON6Iq+6LJeCv9145C3Hte0XusFwOgx8TeaVOiGjoEonui1DuyDQ+zFbn7H7uu/vuurwOyfUI3x0+vJbmIi5T9nMKdQQNxL0NuxnT3SDgvYrujKPgXbvu1jABl/lEMgjQRXtdvj/j7lTlPP7uvpLgXrntBl4O0THe/w8kbintz3ftybjeIq3uIs/uJmlisjl1RfIUpxgRUU/0bzwd7eTQS1xaXc0RXeoRznARm7oSnXjTkwqt2dXlRW0RzclSddsx2dQwbUjgdRtymnSpIpzI+p/dfrVtjkqd/QWOCLJfFakiNHD2r88zDDtNya9CoyrxPjQvK4LRwbMC54wuBvbhgy8ihrMu9r0ib/oqx0Bw9fntYZzWvBd87zPLbwDP/2cB/3ct/wZY+SVoDjhGUwPNMnOVIXObIyNfPp7rEYlC4h+sJU+5PqNfOlQH5dgdIAWDUd3H42031ida+DPCJNR8orhTpqVuOBywj0yY3s0F76pm/6+14IzA4ibqIi+GIzO6Ekua6O/eT07YLg74Qq/Ub1aOMl/oP1RODmWqonlqVo73I2Rd88Bnf5TYAYPWFvHw35xBi/qzoNoW9IpH/62r/9qS8TNTbpD5VzfXIenvJQO4fxpSr4bAY2SCYtcqEvvuX+iS9L529Y1LRQnH5Lr8E1pQYEDkICQogAGgSFgtAkAqBR6ZRatUIH/4Prltv1fr0XAgZQjDAbADRjCGAn3u72Ngu236+DSYHf9/8BAwX9JrTwDhHt6hIZGx0fISPxFiUrGx8cJB4wlOIoCCAAJBwe0ERJTekMLR/1Bl9hXwtZabkoa3FzdXfzVnl/oyAkmhSgLoSUoBgSmo7cmI26boG9XGOvsWepaae3vb/BrbrDyRnHy7H2sNdlfdETz9/l5yHj6e+n7Mmt2fv/tPHd0ReQYMF87gwSHAiOnz+HABPaQhiRYsGFFRlOfNfQYT+IGKlcBDlym0iSv0xS49hx3ccuFrLElDmTZk2bNS1U03iSZ8mdPX0qVMfS488qAzoYULqUaVOnT6Ey7f9gFAtVoFe5WcWaKyWwlURjubRlIEBZs2fRplW79qwBq13npYrEjAEkBsOcbdS6tRZcXl/BthNIlm1hw2zd6mTEpkmTUI/icJELiS6kT3Xn+eVbb2/JoYGviaVD+HDp0omldaYSWRLrK5MfVY5N4AE9zZsd3eb6GTQs0XlImxa+FrVEKjBv5ozi+pOCDUMeMIMWisEnAhQyALgwbAgyUNWbYNfeREiaKEkoCDmSpJgQBkUSMKPAJBmzCE0uuLGOHX58KcvCy+A+xzJTDbdIdMMFsN4A+U2c4IaL0KziVAkpqaem+q+xJmpjJpPs6MrAAQdOeUAMDN6oTY4EoBjFxDH/2JBADQLMg4I9ANy70b0iKADgkwsyIEBGujAh0cUTi3BCChefY1EIFeVJ8MBDpOSGNwYFcfAoCCWMkMJeQuKyLApdK4MYKCpzb8Mh5IqDscaIiGayG+nSkYD3orkPggcIIDHNO9eMMy9l2uCTtidtM3DK3BT960osG1RtADG7NO1LcRCalDhfXIsuEwdAvPM5GUfJjtAEVIyxRVCjaHLGGpGo784k0tgxT1D49FNUIU8x1cxBV33AVUQLXFSlRndZEFI+tAyz0kovPSpTSslcE4IfR42uTyHrAq8Z7bhjcUAIvI0miSFolILOOzMYJr07zQBAz1wBgIZb/RqLIN4p/wC8Ljtio0TWWCoF3m1ZwRSh9FnDog1p2k3xkG1gjKqcODWhDh6k2XwUXhixtx5Wq+EtJLY4oopNBjMgZZfdWApNPR5u5JdDTmvmlLFCGWeHMc44EJejgDlmS0F2VuSCd7YI6aQx7dnnfyTteGi0bq7KaJuXLvMQPfG4kWmrv65EZ0lYhhRoLKSeesKiOYbYkThKtoNrLxD1+uux717ayqcjHUzt09h+mdqs52Bk7i7qTiZsvJlmvJVHfT4bAKH//lixfC50KkMp6KPxTVn1vGtbce/8vJhyoQSAk21D6byYAf2FvQH01APgAesUN9bxnXdvpGwsJae88qMvlwI5m/+Ug4IJYOXQ1bFhGIjjPsyaP4X6KJaXFxRThvH1vvZoixV8BpIgw+TeU0YfHsgzDj7tv6ueXODDBdxQ27rolZ5d2AFlkYob9cS/7XEnXYkrBl1E16frTUl9Fmsgldh3MPcNrzDxu032oPA9HNFGNiMSVhump8EnjWKBr/LR9sawnD6ZUAjZWRf1yjexBw5shgKJYMuiRkHLXYwRnWsAA4SQgCfJJknS0V70gvgk1EnhEw5gRus2xIABMSMN9JmdrKTYGPHQUG9hC1oXLfE7Bk1Qh8TjoRcXB0Yv1lARNzRbDsuIteKhsXFqTKPT+MYsOMaxLYGjY9LYyEA7IsiNwNv/Ix/H5Mc/4iyQB2pkNQo5xkMi0oKDXKRBHrmZTNoikr0hIyITOcdLns+SgCxlbjoJmk+CspKj5N0py2GoxoTiGGd6xrduGQ3jrCyVgVklJd+igZsMk5jFNOYxkZlMZS6Tmc00pjAHZigo6S8ULuIeKtJVIV7mkRCT5GP8judMcY6TnOU05zmXmbwpyTJdplhDG97gpsI1bZvc1KPfQBlKV+5zZ8y4wI3QEK83CHSe0sJjHn/5TVjyk6HvYI87PQfPIcjTfwAIZ0w0IMwBqHMjvQRLQuMYv4aOFCMQcAYC2/CJamIzDdbMpkVrktEscBQdYvSkN0O6UJLudBftaoIE//KjHWQUI5fO6BfzeFZPe4K0jCLl6VPRuEk6eJQoTNWhU6GaVVMelG9WpSBWtRpWB+oUETZVJU6bupeLojM5YnVrssgKQXveM2H51Gc1MhcVve4VQ3F9a1almgeqssSrw3Oq8BT6V8WyIrDiGGxHClu5w75PbWBd7GW1iQ+z+hKtV90LYnOKWdH6zq82nGsBIgu/z1J2apYd7Wvlx9Wnpbayq7VrAFwLW9E29iiPfUhnv2pbu+ZWt5flbUh86w/atla4+SRucRV73Hwktyj4dG5zWVla6C5Sui+jLjuWO7TJ3va523Vrd4P23ZYA17DYBaZ54XsQ2UaOvZJ1b2Ljm/9f9KbjtOGN2XiHq9383k2jOIHCWmWiHATHRMHDbPAANACCCUyYwhW28IUxnOEKg6DADD5wTJPigbJ4QK8iDgCJo2JiFDelA8J8sE00QJYVP0XFJR6xXjO04JkOeLEQbitMf6zjjX44yFnQQF75muS9tpgmL5bJkQ1Q4xTfeMonxpCLiQxjGdvYylWesea0IGSa8lir+50ca8VbX9WCAbRpJbN5zdxmz1o3u2xG838F/Ob05bkad/YYWOUcXDuTl896lmGhx0JoOr/3C4Fur6GLG2c/LwzQk34WgK8Lad1KWtF1DfCgP63p13I61KDOdKMtDS1Eixo3pD61qeuM6k7/sxqzro41rBnd51nTuserBs6udV1qaaS6S+Xl9SVtnWtZCzvRzD72eX39IGAPe9q/dvazw5ps/OJ629S+NrYBG+0tVXs05B73t8H9VG2H1tOv9ra7011mcV/t1suGd7nRHW9qLOF2SE2UQogtoUqbm97K1jc4JKCAARE1EZ/wXy0Vd1RlQMPfNAM4wc99b2tr/ODA4BME4oOBih6iAUFckfZWWop0uRRWBl1ZwL2k5tpym90dB4cDaNWAkd/hGGJgEUR/KFE4CD0KCJbpkG0Dc5nJnLk0d7PNwbE6kFecC8+5QBwASiOCCurkWX6yRse8D6ULZ+D5bpvZoY6LUlzg/wE/RIQAEwB0ilJ0l5odO9EW3e1mczztuijF7BrAcETQXaUluqbKW55Uu2O84HrHN9/7jgvcFRQPkYE4USVe1DPew9H2zXvN313vyO+CT0SAAAQ2gMl5nx3yGRf9418/+lwkIPEKWb3gGM/62Esb7bKHxOwoIAHAC16ztw/a3QH3+acHu/W+fwQ74aT6i/ce99Q/c+6d34jTQ0AB2w+q7afffN0bHPbkzz4raG+jnXPe+GjD/vHf3/k1n78WGxCiBOLjROm//P3ut778Z47+aCFJGsMBvm9l2u/6rM//xI8Bd08Anw8DFOABUgf8+G8BFbABM/ABIRASKLACiy/8OP/Q9cyP9zSwA+9AAbxj/f7tAk9wA0uQBB0PBR9BAoZBiKiuphIQAJuu3Uaw+l6QBruAT5hgE3KwHNZt+eztB+EPA4WQCz6O9iKABYvFBZkQCK8QBmfwCRMhASLgXMzHAhcPA3kwzZxuzriwEpYgIZIQDc9Q0JYwBtMQDzJgT/Zk/8bwBcsQz97w0ebQEegD5MIQAUVQDmUQ9PYuC//wCvBPAiBA5/CQ85DvMMpOA/fwzxKQ1aIQAkQuEpOu/7QQEctvCxcRDCRA5EpuEEPQCg2x8URx4xSxFKlADMjDVwiRFUnRBLPwEiktE2ltAwLPFm8xD2ORFy/tvl5RFrtg+5j/MfWUphBz8RCVMBFbURmnAPqU5BlxMRlhsRod0But8TwaQAK+cBxVkf2gkRt1ERyNUdXC8Q4+zkZ6RBuJERy/MRqx0B7fEUeI4AL8gx4lERTbsdiQcRr3UTI25ABXsR7xcfwa8h7V8SCpABgbwBktosPYysD60PN8kB0nkWF8USLLCsmUrCRZrDMGUuCYzgzj8CFFkmI+codaMiJd0SC70SXfsQGEkQ1j0m1m0iZHkSabMAhlMQprbxvdkPmKsSd9MvT00Ro/Bf9CDpOYUo42cv6uMgCV8imVUQUDBRFupzGI6vImDpcyLyiT0ilxMhSBUhrT8iWrQAI/MBGqo0MI/2ADqMnwVo6lqFEoh3Ip468qrRIuuQD1KIMv34lF4onovA6jBLOPOnItUzLmsrIHCdMKgMgJQFBumoAMsq4Btm7rii6mHnNtItMv/9IjQfEdbbABMMABjrAL7uMC5E7o6A4t4fAn37IvUXMyl+4yrSAekYAKu0ABzOdHPAEU9LKl+BI3/VA3cxM6n1MtUfMgyREC/DE2qyCBFIcsNe87nZMjpVM8xxMrqbMtL7NzHKCEPvEEfZPsVpIPy1MrgXMig5EnF/A98e400dMhq7M+kTI6z3M3w5M8ebM/ARQ/3bM0TZM/CdQtBTRBQUI/KRElGfSu5tMyBzRCJbQiKBQkHf+UQwvUPA/0QS8TA84xHU20JleURUUUQqdTQqfQQy8Uqz4UREM0RkeUPiVUBYePKvPzQnErPjGxMlmyQ+tlQ4hzI2rUQgVSSDEtFt9xA7pv+4B0QZ80MFczHAMxAVI0M5o0Rw10Q3X0Jv+TNRPAESHRIsLUSOXTTYs0Q49UQjexE9k0SLP0/6A0JDXtFGnPAb40StpUTt+UUON0K9fyHWmxT3ayPRXxRiuISHsRTicVSaEAGBWgUR3VHiFVJg21UhH1TBX1Pq/0UfdU+Vo0NRM1HFdHgUqVU09VTEl0RzU0QflEX45hHlX0RWF0TEuUV/0TQV/SEdXvVXGyU5syVIX/FSKXdR+BjwKe1VirE1nNiFKP0VrdkU7XJBt3tUzNtFmZNVXDFVhFkhm3zyID1FvXUTJjVVnF1VLBFE/JsF3J1Ffr81riw0ulFVypdTA/9Vr/NVuR1Dsob1OPlV7dlVxVVVShEgPmcl/flS0jVmIVdlzVNT0p4FwhtmIt1l6/9V37lWr4FNJatWDjFUvnVUud0BpL70fvFGX1EGFpdU4llAICNSBhFjD1dEutMQKcaCpf1lTz1BJlFkDtxWQFVV5jVmWJMhw/cDMNdlqLdmYL9VcvljAVAPACLxFgZyyHqix16Sw/9mqDdWJDFjIDliDh9WiXlAsiIFTwEoSUk+WW/9NqZ5VqDzVtVRJb1dZSN2D7HID4DuGJalMxJ4oxx9Zje/Vu8RZU65VxJTQBdBURPkFGPjM0o4E1jG5QE5Zsy5Zjz7ZBkTRrXRNpu0B01tOEEnNFbhPIZiLGlFZniZZnlfFoFRIMGAMOTuWEUu7wYMNFFRd4g1d4IZd4eTRB//b02PMLPicavDPzxHZd+XVqE3d4FxZcw/ERtXZrgxZWh3YXqRcuz0VJN9Zzr9dsw/dzzXcf65D7hiFwy9d6z5djO7Z41Vd+JdIr31ZBhTZld3ZlZRFAnuBkOPdxj9du7TcfV1UWzyVf9bV7D/Z7VROAS3F8ow+CpVaCXTJ0MdRWn/8Wak+2f5f2f5sWXhmigBH4gBsXYDsXf024plB4hQVWbymThn/zhSmCg200fY23VmW4b3GYf73Xf2eXgoPYK2K4ehP4fpe4flX4iEN4iEe4iEsYiv8iiaUXezl4SPl2b624W114iysRfGn3i3VBh52UiMnYiM1YQbB4cZ84i0GWh9vYG9BYVuMYjn1YifO4ju34jXuYZg14j+WYfv04WQCZiftYkQlZjwX5kMPhjru4hif5hlu4iSEZkWNXH8W4ICc2k/sikRX4Pzu5kuETlGF4k9mVaaUUlcNIlOd3fZ24kQO5al25JGB5lh/5h734khf5lkNZlUmZjnXZloEZJXL/mWJlWZnxt5SP+Y+FWYuJmZkx+ZnJJpmd2ZT305dp2Zq5AZunuZjzNoW72ZtfOZrRl5W50oyfIy+el+LA9ggl2YZPGY/LOZZduI7h+eS4hm7plpctmZt3mY/vWZwd15vZwBkKl3URt5DDOJyp+ZcjuqAhOaFtJBkCKnOHQDQBup7peZs/OvlCukLNWYUUup0iynCHTqXJ2ZgJeqAdupkhuo4t+uQKz5+b86XHuaVdWqd32qcP+pmPti7e2Sz3uTGNDJw1uDdnuqS9YHPR2ZCzeZBh2qmvOaqXeap5+qet+pxzlpOnWau7mrGUWo0nuIrHWqC5OqareaKrepSxN61R/1WWxXqrgxqoWViuvVqEZXeN0Vqv8RqI1Xqt2Vqi6xqwc6Osp9ivWxmx7XqGqbqnC5uiD9ux4UGx+/qsG9uyJ1uya5mwHdmz4fqTOTuwe3mw77qjPTqyQbu0tZmkXxu2YxtHUTuvXfuysTqfK/uzU/u27Vm0R1uqw7qpfTu4H3qpm3W3i5u1bfuxIZu5m9u0T3u55/q4zXqDiZu657m2n9u5Bdu7p5u6Z9tTobu7VRukwZuSxfu3W9u4dXu4y7i4t7u8v5u+w1u61Xu9RzpS2bu93RuTlVu/edu8Oxu4/9uws3u55zu9A5q76xu/G1zAGRy9J5zCK1ykHfy+JbzAe/87tP0bnwE8weUbs8FanRdYu0l8lUl4sxU8xYfZxBkWxXO7rQMcxCVawhf8vDF8v/mbx8l7wyHcwoNcyId8xy9ctoFcx2k7w/Pbvpu8yJG8uL3zyHvcx5PVySMcypfct/OSyn9cybccy1fby7+8tIHOeEDMJNVcczCSmKBszeFcKZgsmd48ztd8zp+JJO08yTZnuT8TzTMy0AV90Am90Ac97Dj7zJO8pJPzMRbdnKf80SV90im90i390jE90zV9002YCYhKW4TE0aPAOyMdEjwdCh6ga2fxa4XKljj9C0r9O6NXEjahMSoQeo9a7cRSGY6gSPhFbskF2CNBloiKE4r/AXo0hHSCXdlf3Qu6PApwGvFoQYiWN9p/lxZOXQpEJHxGRHVpRNEjIduZIO7wDwq6HejAvdlfA6VrhUTmrqEjYVTCoza6/d1ZeheyHQoywD7MnUQ+83Ib4yjtIN8JiKi6/d8xWusCXt3/J+Hb/VdWBHObQOBTMF2MHUdIBHOPYKAWHttzhxZRZQrQnd3VUHHuYwP2nQAOcOSr6KUYvgrS3d67rhJOBOJVSKVbNxfEfd6joN5T6jt+XtQfIdt/RHvyw+dZRKUa/eWvYOm7vW7/uRIwQRMu/umt3eVpgZ1IpHPO5OlJndU9cENIJAOsA34x3hhYPdaZXgq88+lxHZdY/0EYbMnt93nW1/7u8T7v9X7v+b7vJz3bLVg5owD6WkcIDJDWoYFYEwiortFa1MDwbxfvCX8KjjYNQG7icaGdpUDzqaDyywAaKB4sd11DSEEKpCkYriNJl/cQpMh2zj0NRIRETJ9DUL9H4kbyab8KnmjwM6HWBZcy4D7Xo2D3Ub33L94S8j2DFKfb2SkNsu73G2HboURE/If5N8T5Ex76mb75+x1NtOgB4oXzWaGmCSUvpidJ5z38dankBa8IZKT7pcCfsif5HyHl8wIZgurph1/l5x8ICAoAsWg8IpPKJbPpfEKj0im1ar1is8sE4QJwOI4YAoZBkADMEe1SbXQTI/8EhnFcPqcJa/ZRITRyeS01/FEQnHXxEV0cJjwcSRBkKBEOGSIKKmpucnZ6foKGGlUqQegB+CFifMIRtSaZrqVGrnL6DRH5JRiBAUDscdG5SuwqplI8AmAMPURO9v4SBRcxEIteY2drb3MvRQNM9z5QTI7hAow7THq+tsoxjJf/EaWvKz4cHoY1E0DwhmWIdEaQg0MYkvFJlU8Bo0MSCAIU+JBIQTIIu2HMqHEjRyQBHUIkcmmeHAIUhHXiko+OykN03gEYiavkyY42b+LMqXMnz54+fwINKnQo0aJGjyJNqnQp06ZOn0KNKnUq1apWr2LNqnUr165ev4INK3Ys2bL/Zs+iTat2Ldu2bt/CjSt3Lt26du/izat3L9++fv8CDixY1Jg5SMwUG6x48c2WhyKQUrThVBLEjC9j1hi5k6kGSixnDi1aVORb+BwYkqAg0poHJSX4KzLOIQQzjd5EKrir4ilDlgyPDi78SWkhp1GRAeBMDoQMeIowb+bggR/PRiIxAE0k0gZTCZxTGC5+PJLiCo5XBzeH9yGEBR9xgZBeNoEwlgnl88e6H/n+482jR4BnwciRiRHRSTDdfEWA8cBkCfgRHnPIPeefhaMBWB9yA87hWj5hyHZJAv4sSIQpBHDhCBcOxIdOQedcGKOM2zzQy4w34hhKiTny2KOPPwIZGqSQQxJZpJFHIpmkkksy2aSTT0IZpZRTLhUEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis was performed using trials that reported the timing for an acute myocardial infarction (N=66,635 patients) and sudden death (N=19,390 patients). An excess number of infarctions and sudden deaths occurred in the morning between the hours of 6 am and 12 pm, indicating a circadian pattern to their occurrence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kangro, T, Henriksen, E, Jonason, T, et al. Am J Cardiol 1997; 79:1507.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_35_7743=[""].join("\n");
var outline_f7_35_7743=null;
